Respiratory syncytial virus vaccine as well as preparation method and application thereof
By introducing polymerizing elements and specific amino acid-substituted pre-fusion F proteins into RSV vaccines, combined with lipid nanoparticle delivery, the problem of neutralizing antibody induction in RSV vaccines was solved, achieving highly efficient immunoprotective effects.
Patent Information
- Application Number
- CN202311404395.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-05-19
- Filing Date
- 2023-10-27
- Publication Date
- 2024-11-22
AI Technical Summary
Currently, there is no effective RSV vaccine, and it is difficult to induce high-titer neutralizing antibodies. The instability of the pre-fusion F protein has become a challenge in research and development.
An immune composition containing or encoding pre-fusion hRSV F protein was designed. The F protein was stabilized by introducing polymerizing elements and specific amino acid substitutions into its amino acid sequence, and the efficiency of the immune response was improved by using lipid nanoparticles or cationic liposomes as delivery formulations.
It achieved an effective neutralizing antibody response, enhanced immune protection against RSV, and improved vaccine stability and immunization efficiency.
Smart Images

Figure CN118987189A_ABST
Abstract
Description
[0001] This application claims the priority of a Chinese patent application filed on May 19, 2023 (application number: 202310570847.2, invention name: Respiratory syncytial virus vaccine, preparation method and application thereof), and part of the contents of the Chinese patent application are incorporated herein by reference in their entirety. Technical Field
[0002] The present disclosure relates to the field of gene medicine technology, and in particular to a respiratory syncytial virus vaccine and a preparation method and application thereof. Background Art
[0003] The statements herein merely provide background information related to the present disclosure and do not necessarily constitute prior art.
[0004] Respiratory syncytial virus (RSV) is the most common pathogen of bronchiolitis and pneumonia in infants and young children, which seriously endangers the health of infants and young children. RSV infection does not provide lasting immunity, so repeated infection is very common. RSV infection is global and can cause local outbreaks, becoming a global public health problem. However, there is currently no approved RSV vaccine.
[0005] The RSV genome is about 15 to 16 kb in size and encodes 11 proteins, including 8 structural proteins and 3 non-structural proteins (NS1, NS2, and M2-2). The structural proteins include 3 transmembrane surface proteins (G, F, SH), 2 matrix proteins (M and M2-1), and 3 nucleocapsid proteins (L, N, and P). G protein mediates the binding of the virus to the host cell, and F protein mediates the fusion of the virus and the host cell membrane, allowing the virus to enter the cell. Both are essential for viral replication, and both contain B cell and T cell epitopes, which are the most important viral antigen proteins that stimulate the body to produce humoral and cellular immunity. The G protein coding region varies greatly, and can be divided into subtype A and subtype B based on its variation. The neutralizing antibodies induced by G protein are subtype specific; the F protein coding region is highly conserved, and the amino acid sequences of F proteins of subtype A and subtype B are at least 90% identical, so the neutralizing antibodies induced by F protein can inhibit RSV infection of both subtypes A and B at the same time. The structure of F protein changes dynamically. It is first transcribed and translated into a single inactive polypeptide (F0) in the host cell. It is then cleaved for the first time by the host cell furin protease to generate a partially cleaved prefusogenic protein. Then, a second furin protease cleavage occurs to generate F2 and F1 subunits. The two subunits are connected into a monomer by two disulfide covalent bonds. Then, the three monomers form a metastable functional prefusion protein trimer. After that, it can undergo conformational rearrangement to form a thermodynamically stable postfusion protein without further treatment. The timing and cellular location of the two furin protease cleavages and conformational rearrangements are not yet fully understood, and the conditions that induce conformational rearrangements are also unclear. On the surface of F protein, the antigenic epitopes related to neutralization activity are mainly I, II, III, IV, V, and of which epitopes I, II, III and IV are present in the F protein before and after fusion; V and It is a specific antigenic site of the F protein before fusion. The F protein after fusion does not have these two epitopes. Epidemiological studies have shown that RSV neutralizing antibodies can prevent severe RSV-ALRI. The neutralizing activity of monoclonal antibodies is 10 to 100 times that of monoclonal antibodies against epitope II, and the neutralizing activity of monoclonal antibodies against epitope VIII is also very high. Therefore, most RSV neutralizing activities in serum are only directed against the prefusion F protein antigenic site. The inventors realized that inducing high titer neutralizing antibodies is the main goal of developing RSV vaccines, and the prefusion F protein with specific antigenic epitopes has become the most popular RSV vaccine target. However, the prefusion F protein is essentially an unstable protein, and making various stability modifications to it without losing important antigenic epitopes is one of the difficulties in the development of RSV vaccines. Summary of the invention
[0006] In some embodiments, the present disclosure provides an immune composition comprising or encoding a human respiratory syncytial virus (hRSV) antigen, which can induce an effective neutralizing antibody response against human respiratory syncytial virus (hRSV).
[0007] Some aspects of the present disclosure provide an immune composition comprising or encoding a human respiratory syncytial virus (hRSV) antigen, wherein the immune composition is selected from a nucleic acid immune composition, a polypeptide immune composition, or a viral immune composition.
[0008] In some embodiments, the antigen is a pre-fusion hRSV F protein, and the amino acid sequence of the pre-fusion hRSV F protein includes a TM sequence and a multimerization element.
[0009] In some embodiments, the amino acid sequence of the polymerizing element is as shown in Seq ID NO.1-12, Seq ID NO.14-15.
[0010] In some embodiments, the amino acid sequence of the polymerizing element is one of those shown in Seq ID NO.7 and Seq ID NO.12.
[0011] In some embodiments, the P27 sequence of the pre-fusion hRSV F protein variant is substituted with a GS sequence.
[0012] In some embodiments, the GS sequence comprises (GnS)m, (GGGGS)o, GGSGGGGSGG, GGSGGGGG, GSGSGSGS, (Gly)p, (EAAAK)q, such as Seq ID NO.48-61, Seq ID NO.74 (wherein n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15 or 20; m is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15 or 20; o is an integer from 1 to 5; p is an integer from 1 to 40; q is an integer from 1 to 5).
[0013] In some embodiments, the GS sequence amino acid sequence is shown as Seq ID NO.74.
[0014] In some embodiments, the amino acid sequence of the pre-fusion hRSV F protein variant includes at least one of an S46G substitution, an N67I substitution, an E92D substitution, a P102A substitution, an A149C substitution, an S155C substitution, an S190F substitution, a V207L substitution, an S290C substitution, an L373R substitution, an S215P substitution, an I379V substitution, an M447V substitution, a Y458C substitution, a K465Q substitution, a D486C substitution, and a D489C substitution.
[0015] In some embodiments, the amino acid sequence of the pre-fusion hRSV F protein includes at least one of an S155C substitution, an S190F substitution, a V207L substitution, an S290C substitution, and / or the P27 sequence of the pre-fusion hRSV F protein is substituted with a GS sequence.
[0016] In some embodiments, the amino acid sequence of the hRSV F protein before fusion includes S155C substitution, S190F substitution, V207L substitution, and S290C substitution; the P27 sequence of the hRSV F protein before fusion is replaced with the GS sequence shown in Seq ID NO.74; the hRSV F protein before fusion includes a multimerization element as shown in one of Seq ID NO.7 and Seq ID NO.12.
[0017] In some embodiments, the amino acid sequence of the hRSV F protein before fusion includes S155C substitution, S190F substitution, V207L substitution, and S290C substitution; the P27 sequence of the hRSV F protein before fusion is replaced with the GS sequence shown in Seq ID NO.74; the hRSV F protein before fusion includes a multimerization element as shown in one of Seq ID NO.7 and Seq ID NO.12; the amino acid sequence of the hRSV F protein before fusion also includes at least one of S46G substitution, N67I substitution, E92D substitution, P102A substitution, A149C substitution, L373R substitution, S215P substitution, I379V substitution, M447V substitution, Y458C substitution, K465Q substitution, D486C substitution, and D489C substitution.
[0018] In some embodiments, the amino acid sequence of the pre-fusion hRSV F protein includes at least one of an S155C substitution, an S190F substitution, a V207L substitution, an S290C substitution, a D486C substitution, and a D489C substitution.
[0019] In some embodiments, the amino acid sequence of the pre-fusion hRSV F protein includes at least one of an S155C substitution, an S190F substitution, a V207L substitution, an S290C substitution, a D486C substitution, a D489C substitution, and / or the P27 sequence of the pre-fusion hRSV F protein is replaced with a GS sequence.
[0020] In some embodiments, the amino acid sequence of the pre-fusion hRSV F protein includes an S155C substitution, an S190F substitution, a V207L substitution, an S290C substitution, a D486C substitution, a D489C substitution, and / or the P27 sequence of the pre-fusion hRSV F protein is replaced with a GS sequence as shown in Seq ID NO.74, and / or the pre-fusion hRSV F protein includes a multimerization element as shown in one of Seq ID NO.7 and Seq ID NO.12.
[0021] In some embodiments, the amino acid sequence of the hRSV F protein before fusion includes S155C substitution, S190F substitution, V207L substitution, S290C substitution, D486C substitution, and D489C substitution, and the P27 sequence of the hRSV F protein before fusion is replaced with the GS sequence shown in Seq ID NO.74, and the hRSV F protein before fusion includes a multimerization element as shown in one of Seq ID NO.7 and Seq ID NO.12; the amino acid sequence of the hRSV F protein before fusion also includes at least one of S46G substitution, N67I substitution, E92D substitution, P102A substitution, A149C substitution, L373R substitution, S215P substitution, I379V substitution, M447V substitution, Y458C substitution, and K465Q substitution.
[0022] In some embodiments, the pre-fusion hRSV F protein variant includes an amino acid sequence in which at least one of the amino acids of the F2 sequence, the RR1 sequence, the RR2 sequence, the 525-529 sequence, or the 551-574 sequence is missing consecutively or intermittently.
[0023] In some embodiments, the amino acid sequence of the pre-fusion hRSV F protein is shown as Seq ID NO.62, Seq ID NO.64, Seq ID NO.66, Seq ID NO.68, Seq ID NO.70, Seq ID NO.72, Seq ID NO.76, and Seq ID NO.78.
[0024] In some embodiments, the amino acid sequence of the hRSV F protein before fusion is shown as Seq ID NO.62, Seq ID NO.64, Seq ID NO.66, Seq ID NO.70, Seq ID NO.76, and Seq ID NO.78.
[0025] In some embodiments, the amino acid sequence of the hRSV F protein before fusion is shown as Seq ID NO.62, Seq ID NO.66, Seq ID NO.70, Seq ID NO.76, and Seq ID NO.78.
[0026] In some embodiments, the multimerization element of the pre-fusion hRSV F protein can also be selected from the amino acid sequences shown in Seq ID NO.1-12 and Seq ID NO.14-15.
[0027] In some embodiments, the immune composition is a nucleic acid immune composition.
[0028] In some embodiments, the nucleic acid immune composition comprises a nucleic acid molecule.
[0029] In some embodiments, the nucleic acid molecule comprises a DNA molecule and / or an RNA molecule.
[0030] In some embodiments, the DNA molecule comprises a linear DNA molecule and / or a circular DNA molecule.
[0031] In some embodiments, the RNA molecule comprises mRNA or circular RNA.
[0032] In some embodiments, the mRNA molecule includes an open reading frame (ORF), and the nucleotide sequence of the open reading frame (ORF) is shown as Seq ID NO.63, Seq ID NO.65, Seq ID NO.67, Seq ID NO.69, Seq ID NO.71, Seq ID NO.73, Seq ID NO.77, Seq ID NO.79, and Seq ID NOs.84-103.
[0033] In some embodiments, the mRNA molecule includes an open reading frame (ORF), and the nucleotide sequence of the open reading frame (ORF) is shown as Seq ID NO.63, Seq ID NO.67, Seq ID NO.71, Seq ID NO.77, Seq ID NO.79, and Seq ID NOs.84-103.
[0034] In some embodiments, the mRNA molecule includes an open reading frame (ORF), and the nucleotide sequence of the open reading frame (ORF) is shown as Seq ID NO.63, Seq ID NO.71, Seq ID NO.77, Seq ID NO.79, Seq ID NO.84-87, and Seq ID NO.92-103.
[0035] In some embodiments, the mRNA molecule includes an open reading frame (ORF), and the nucleotide sequence of the open reading frame (ORF) is shown in Seq ID NO.63, Seq ID NO.77, Seq ID NO.79, Seq ID NO.84-87, and Seq ID NO.96-103.
[0036] In some embodiments, the mRNA molecule includes an open reading frame (ORF), and the nucleotide sequence of the open reading frame (ORF) is shown in Seq ID NO.67.
[0037] In some embodiments, the mRNA molecule includes an open reading frame (ORF), and the nucleotide sequence of the open reading frame (ORF) is shown in Seq ID NO.71.
[0038] In some embodiments, in some embodiments, the nucleotide sequence of the multimerization element in the open reading frame (ORF) can also be as shown in Seq ID NO.36-47, Seq ID NO.13.
[0039] In some embodiments, the immunological composition comprises a delivery formulation; in some embodiments, the delivery formulation comprises lipid nanoparticles or cationic liposomes.
[0040] In some embodiments, the mRNA and a delivery formulation are mixed to form an immunological composition; the delivery formulation comprises lipid nanoparticles or cationic liposomes.
[0041] In some embodiments, the present disclosure provides an isolated mRNA, the coding region nucleic acid sequence of the mRNA encodes a pre-fusion hRSV F protein, and the amino acid sequence of the pre-fusion hRSV F protein includes a TM sequence and a multimerization element; preferably, the multimerization element amino acid sequence is as shown in Seq ID NO.1-12, Seq ID NO.14-15; preferably, the multimerization element amino acid sequence is as shown in one of Seq ID NO.7 and Seq ID NO.12.
[0042] In some embodiments, the mRNA further comprises at least one of a 5' cap, a 5' UTR, a 3' UTR, and a 3' poly A tail.
[0043] In some embodiments, the 5' end cap is selected from ARCA, mCAP, dmCAP, tmCAP, m7G(5"")ppp(5"")(2""OMeA)pG, m7(3""OMeG)(5"")ppp(5"")(2""OMeA)pG, m7(3""OMeG)(5"")ppp(5"")(2""OMeG)pG, dmCAP or m7G(5"")ppp(5"")(2""OMeG)pG;
[0044] In some embodiments, the 5' end cap is m7Gppp(5')(2'-OMeA)pG.
[0045] In some embodiments, the 3' poly A tail is 50-200 in length.
[0046] In some embodiments, the 3' poly A tail is 80-200 nt in length.
[0047] In some embodiments, the 3' poly A tail has a length of 80 to 120. In some embodiments, the 3' poly A tail has a length of 120.
[0048] In some embodiments, the length of the 5'UTR is preferably 10 to 200 nucleotides.
[0049] In some embodiments, the 5'UTR is 15 to 100 nucleotides in length.
[0050] In some embodiments, the 5'UTR nucleotide sequence is as shown in Seq ID NOs. 16-18.
[0051] In some embodiments, the 5'UTR nucleotide sequence is as shown in Seq ID NO.16.
[0052] In some embodiments, the 3'UTR sequence is as shown in Seq ID NOs. 19-21.
[0053] In some embodiments, the 3'UTR sequence is as shown in Seq ID NO.19.
[0054] In some embodiments, one or more uridines in the mRNA are replaced with modified nucleosides.
[0055] In some embodiments, the modified nucleoside is pseudouridine (ψ), N1-methyl-pseudouridine (m1ψ), or 5-methyl-uridine (m5U) (m5U).
[0056] In some embodiments, the modified nucleoside is N1-methyl-pseudouridine (m1ψ).
[0057] In some embodiments, the present disclosure provides an isolated DNA, wherein the DNA is obtained by reverse transcription of the isolated mRNA nucleic acid, or the DNA is a sequence capable of transcribing the isolated mRNA.
[0058] In some embodiments, the present disclosure provides a biological material, which includes any one of an expression cassette, a vector, an engineered bacterium or a cell line, and the biological material contains or expresses the isolated mRNA or the isolated DNA. BRIEF DESCRIPTION OF THE DRAWINGS
[0059] In order to more clearly illustrate the specific embodiments of the present disclosure or the technical solutions in the prior art, the drawings required for use in the specific embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some embodiments of the present disclosure. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying any creative work.
[0060] Figure 1 A schematic diagram of the hRSV F protein wild type is shown.
[0061] Figure 2 Schematic representation of hRSV F protein variants is shown.
[0062] Figure 3 A schematic diagram of the mouse experiment evaluation process is shown.
[0063] Figure 4 The flow cytometry detection of TNFα+CD4+ and TNF-α+CD8+ T cells in Example 5 is shown.
[0064] Figure 5 The ELISA detection of IFN-γ and L4 in the cell culture supernatant in Example 5 is shown.
[0065] Figure 6 The RSV neutralizing antibody titer in the mouse serum in Example 5 is shown.
[0066] Figure 7 The statistical graph of RSV-F protein-specific IgG antibody titer in mouse serum detected by ELISA in Example 6 is shown.
[0067] Figure 8 The flow cytometry detection of TNFα+CD4+ and TNF-α+CD8+ T cells in Example 6 is shown.
[0068] Fig. 9 The ELISA in Example 6 for detecting IFN-γ and IL2 in the cell culture supernatant is shown.
[0069] Fig.10 The ELISA in Example 6 for detecting IL4 and IL10 in the cell culture supernatant is shown.
[0070] Fig.11 RSV neutralizing antibody titers in mouse sera in Example 6 are shown.
[0071] Fig.12 The flow cytometry detection of TNFα+CD4+ and TNF-α+CD8+ T cells in Example 7 is shown.
[0072] Fig.13 The flow cytometry detection of IFN-γ+CD4+ and IFN-γ+CD8+ T cells in Example 7 is shown.
[0073] Fig.14 The ELISA in Example 7 for detecting IFN-γ and IL2 in the cell culture supernatant is shown.
[0074] Fig.15 The ELISA in Example 7 for detecting IL4 and IL10 in the cell culture supernatant is shown.
[0075] Fig.16 RSV neutralizing antibody titers in mouse sera in Example 7 are shown.
[0076] Fig.17 The flow cytometry detection of TNFα+CD4+ and TNF-α+CD8+ T cells in Example 8 is shown.
[0077] Fig.18 The flow cytometry detection of IFN-γ+CD4+ and IFN-γ+CD8+ T cells in Example 8 is shown.
[0078] Fig.19 The ELISA in Example 8 for detecting IFN-γ and IL2 in the cell culture supernatant is shown.
[0079] Fig. 20 The ELISA in Example 8 for detecting IL4 and IL10 in the cell culture supernatant is shown.
[0080] Fig.21 RSV neutralizing antibody titers in mouse sera in Example 8 are shown.
[0081] Fig. 22 The RSV neutralizing antibody titers in the mouse sera in Example 9 are shown.
[0082] Fig.23 RSV neutralizing antibody titers in mouse sera in Example 11 are shown.
[0083] Fig.24 RSV neutralizing antibody titers in mouse sera in Example 12 are shown.
[0084] Fig.25 RSV neutralizing antibody titers in mouse sera in Example 12 are shown.
[0085] Fig.26 RSV neutralizing antibody titers in mouse sera in Example 12 are shown.
[0086] Fig. 27 The figure shows the trend of the weight change of mice in Example 13.
[0087] Fig.28 A trend graph of the weight change rate of mice in Example 13 is shown.
[0088] Fig.29 The statistical graph of RSV-F protein-specific IgG antibody titer in mouse serum detected by ELISA in Example 13 is shown.
[0089] Fig.30 The results of the RSV-A / B strain neutralizing antibody titer detection in mouse serum in Example 13 are shown.
[0090] Fig.31 The results of virus titer detection in lung tissue of mice after RSV infection in Example 13 are shown.
[0091] Fig.32 The results of lung tissue pathology of mice infected with RSV in Example 13 are shown. DETAILED DESCRIPTION
[0092] Figure 1 A schematic diagram of the wild-type hRSV F protein before fusion is shown; Figure 2 A schematic diagram of one of the prefusion hRSV F proteins (prefusion hRSV F protein variants) of the immunological composition antigens described in the present disclosure is shown.
[0093] is furin protease cleavage; SP is the signal peptide sequence; P27 is the 27aa peptide sequence removed after cleavage; RR1 is repeat folding region 1, spanning 137 to 216 amino acid residues of the wild type of hRSVF protein before fusion, including the fusion peptide and the heptad repeat sequence A (HRA); RR2 is repeat folding region 2, which forms the C-terminal stem in the spike of the hRSVF protein before fusion, including the heptad repeat sequence B (HRB) relocated to the other side of the head of the RSVF protein before fusion; the 525-529 sequence is a sequence connecting RR2 and TM; TM is the transmembrane region sequence; the 551-574 sequence is a sequence attached to the C-terminus of the TM sequence.
[0094] F2 usually contains amino acid residues 26 to 109 of the F0 precursor; F1 usually contains amino acid residues 137 to 574 of the F0 precursor; F1 and F2 are linked by disulfide bonds to form a heterodimer, which is called the RSVF "protomer".
[0095] In the present disclosure, "pre-fusion hRSV F protein wild type" or "pre-fusion hRSV F protein (wild type)" refers to the wild type pre-fusion hRSV F protein, which has not been artificially modified or mutated.
[0096] Figure 2 The C-terminus shown on the top may be missing or selected from at least one of the TM sequence, the 525-529 sequence, the 551-574 sequence, and the multimerization element. In some embodiments, the C-terminus of the hRSVF protein variant before fusion described in the present disclosure is missing. In some embodiments, the C-terminus of the hRSVF protein variant before fusion is a TM sequence. In some embodiments, the C-terminus of the hRSVF protein variant before fusion is a TM sequence and a multimerization element connected in sequence, wherein the C-terminus of the TM sequence is connected to the N-terminus of the multimerization element. In some embodiments, the C-terminus of the hRSV F protein variant before fusion is a TM sequence. In some embodiments, the C-terminus of the hRSVF protein variant before fusion is a TM sequence, a 551-574 sequence, and a multimerization element connected in sequence, wherein the C-terminus of the TM sequence is connected to the 551-574 sequence, and the C-terminus of the 551-574 sequence is connected to the N-terminus of the multimerization element. In some embodiments, the C-terminus of the hRSVF protein variant before fusion is a multimerization element.
[0097] The multimerization elements described in the present disclosure include dimerization elements, trimerization elements, tetramerization elements and oligomerization elements, which, when used in combination with the hRSV F protein in the present disclosure, can lead to the formation of a multimeric hRSV F protein complex; the multimerization element can be located at the N-terminus or C-terminus of the hRSV F protein, and its coding sequence is usually placed in the 5' or 3' frame of the coding sequence at the nucleic acid level.
[0098] In some embodiments, the dimerization element can be selected from, for example, the dimerization element / domain of heat shock protein, the immunoglobulin Fc domain and the leucine zipper (the dimerization domain of the basic region leucine zipper transcription factor), and the specific amino acid sequence is shown in Seq ID NO.1-2. The trimerization and tetramerization elements can be selected from, for example, engineered leucine zippers (engineered helical coiled peptides in a parallel trimer state), the fibrin fold domain of Enterobacteriaceae phage T4, GCN4PLL, CCN4-PLI, p53, GCN4, and the specific amino acid sequence is shown in Seq ID NO.3-12 (trimerization) and SeqID NO.14-15 (tetramerization)).
[0099] The hRSV F protein variants before fusion described in the present disclosure are F proteins that have been artificially mutated and transformed, and the mutations and transformations (including but not limited to amino acid residue substitutions, amino acid residue insertions and / or additions, amino acid residue deletions and covalent modifications to the amino acid sequence, etc.) are obtained by mutation and transformation of the wild-type hRSV F protein before fusion to meet the amino acid sequence of the hRSV F protein before fusion. In some embodiments of the present disclosure, "hRSV F protein before fusion" is not described as "hRSV F protein wild type before fusion" or "hRSV F protein (wild type) before fusion", then "hRSV F protein before fusion" is hRSV F protein variants before fusion.
[0100] In some embodiments, the GS sequence comprises, for example, (GnS)m, (GGGGS), GGSGGGGSGG, GGSGGGGG, GSGSGSGS, (Gly)p, (EAAAK)q, such as Seq ID NO.48-61, Seq ID NO.74 (wherein n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15 or 20; m is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15 or 20; o is an integer from 1 to 5; p is an integer from 1 to 40; q is an integer from 1 to 5). Further, in some embodiments, the amino acid sequence of the GS sequence is as shown in Seq ID NO.74, or, the amino acid sequence encoded by the sequence optimization is as shown in the nucleotide sequence of Seq ID NO.74.
[0101] In some embodiments, the present disclosure provides an immune composition comprising or encoding a human respiratory syncytial virus (hRSV) antigen, which can induce an effective neutralizing antibody response against human respiratory syncytial virus (hRSV).
[0102] Some aspects of the present disclosure provide an immune composition comprising or encoding a human respiratory syncytial virus (hRSV) antigen, wherein the immune composition is selected from a nucleic acid immune composition, a polypeptide immune composition, or a viral immune composition.
[0103] In some embodiments, the antigen is a pre-fusion hRSV F protein, and the amino acid sequence of the pre-fusion hRSV F protein includes a TM sequence and a multimerization element.
[0104] In some embodiments, the amino acid sequence of the polymerizing element is as shown in Seq ID NO.1-12 and Seq ID NO.14-15.
[0105] In some embodiments, the amino acid sequence of the polymerizing element is one of those shown in Seq ID NO.7 and Seq ID NO.12.
[0106] In some embodiments, the P27 sequence of the pre-fusion hRSV F protein variant is substituted with a GS sequence.
[0107] In some embodiments, the GS sequence comprises (GnS)m, (GGGGS)o, GGSGGGGSGG, GGSGGGGG, GSGSGSGS, (Gly)p, (EAAAK)q, such as Seq ID NO.48-61, Seq ID NO.74 (wherein n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15 or 20; m is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15 or 20; o is an integer from 1 to 5; p is an integer from 1 to 40; q is an integer from 1 to 5).
[0108] In some embodiments, the GS sequence amino acid sequence is shown as Seq ID NO.74.
[0109] In some embodiments, the amino acid sequence of the pre-fusion hRSV F protein variant includes at least one of an S46G substitution, an N67I substitution, an E92D substitution, a P102A substitution, an A149C substitution, an S155C substitution, an S190F substitution, a V207L substitution, an S290C substitution, an L373R substitution, an S215P substitution, an I379V substitution, an M447V substitution, a Y458C substitution, a K465Q substitution, a D486C substitution, and a D489C substitution.
[0110] In some embodiments, the amino acid sequence of the pre-fusion hRSV F protein includes at least one of an S155C substitution, an S190F substitution, a V207L substitution, an S290C substitution, and / or the P27 sequence of the pre-fusion hRSV F protein is substituted with a GS sequence.
[0111] In some embodiments, the amino acid sequence of the hRSV F protein before fusion includes S155C substitution, S190F substitution, V207L substitution, S290C substitution; the P27 sequence of the hRSV F protein before fusion is replaced with the GS sequence shown in Seq ID NO.74; the hRSV F protein before fusion includes a multimerization element as shown in one of Seq ID NO.7 and Seq ID NO.12.
[0112] In some embodiments, the amino acid sequence of the hRSV F protein before fusion includes S155C substitution, S190F substitution, V207L substitution, and S290C substitution; the P27 sequence of the hRSV F protein before fusion is replaced with the GS sequence shown in Seq ID NO.74; the hRSV F protein before fusion includes a multimerization element as shown in one of Seq ID NO.7 and Seq ID NO.12; the amino acid sequence of the hRSV F protein before fusion also includes at least one of S46G substitution, N67I substitution, E92D substitution, P102A substitution, A149C substitution, L373R substitution, S215P substitution, I379V substitution, M447V substitution, Y458C substitution, K465Q substitution, D486C substitution, and D489C substitution.
[0113] In some embodiments, the amino acid sequence of the hRSV F protein before fusion includes S155C substitution, S190F substitution, V207L substitution, and S290C substitution; the P27 sequence of the hRSV F protein before fusion is replaced with the GS sequence shown in Seq ID NO.74; the hRSV F protein before fusion includes a multimerization element as shown in one of Seq ID NO.7 and Seq ID NO.12; the hRSV F protein variant before fusion includes an amino acid sequence in which at least one of the amino acids of the F2 sequence, the RR1 sequence, the RR2 sequence, the 525-529 sequence, or the 551-574 sequence is continuously or intermittently missing.
[0114] In some embodiments, the amino acid sequence of the pre-fusion hRSV F protein includes at least one of an S155C substitution, an S190F substitution, a V207L substitution, an S290C substitution, a D486C substitution, a D489C substitution, and / or the P27 sequence of the pre-fusion hRSV F protein is replaced with a GS sequence.
[0115] In some embodiments, the amino acid sequence of the hRSV F protein before fusion includes S155C substitution, S190F substitution, V207L substitution, S290C substitution, D486C substitution, and D489C substitution, and the P27 sequence of the hRSV F protein before fusion is replaced with the GS sequence shown in Seq ID NO.74, and the hRSV F protein before fusion includes a multimerization element as shown in one of Seq ID NO.7 and Seq ID NO.12.
[0116] In some embodiments, the amino acid sequence of the hRSV F protein before fusion includes S155C substitution, S190F substitution, V207L substitution, S290C substitution, D486C substitution, and D489C substitution, and the P27 sequence of the hRSV F protein before fusion is replaced with the GS sequence shown in Seq ID NO.74, and the hRSV F protein before fusion includes a multimerization element as shown in one of Seq ID NO.7 and Seq ID NO.12; the amino acid sequence of the hRSV F protein before fusion also includes at least one of S46G substitution, N67I substitution, E92D substitution, P102A substitution, A149C substitution, L373R substitution, S215P substitution, I379V substitution, M447V substitution, Y458C substitution, and K465Q substitution.
[0117] In some embodiments, the amino acid sequence of the hRSV F protein before fusion includes S155C substitution, S190F substitution, V207L substitution, S290C substitution, D486C substitution, and D489C substitution, and the P27 sequence of the hRSV F protein before fusion is replaced with the GS sequence shown in Seq ID NO.74, and the hRSV F protein before fusion includes a multimerization element as shown in one of Seq ID NO.7 and Seq ID NO.12; the hRSV F protein variant before fusion includes an amino acid sequence in which at least one of the amino acids of the F2 sequence, the RR1 sequence, the RR2 sequence, the 525-529 sequence, or the 551-574 sequence is continuously or intermittently deleted.
[0118] In some embodiments, the pre-fusion hRSV F protein variant includes an amino acid sequence in which at least one of the amino acids of the F2 sequence, the RR1 sequence, the RR2 sequence, the 525-529 sequence, or the 551-574 sequence is continuously or intermittently deleted.
[0119] In some embodiments, amino acids 98 to 109 of the hRSV F protein variant F2 sequence before fusion are continuously or intermittently missing at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 amino acid sequences.
[0120] In some embodiments, amino acids 137 to 144 of the RR1 sequence of the hRSV F protein variant before fusion are continuously or intermittently missing at least 1, 2, 3, 4, 5, 6, 7, or 8 amino acid sequences.
[0121] In some embodiments, amino acids 504 to 524 of the hRSV F protein variant RR2 sequence before fusion are continuously or intermittently missing at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or 21 amino acid sequences.
[0122] In some embodiments, the amino acid sequence 525-529 of the hRSV F protein variant before fusion lacks at least 1, 2, 3, 4, or 5 amino acid sequences continuously or intermittently.
[0123] In some embodiments, the amino acid sequence 551-574 of the hRSV F protein variant before fusion lacks at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 amino acid sequences continuously or intermittently.
[0124] The positions of the amino acid sequences described in the present disclosure, such as S46G substitution, E92D substitution, P102A substitution, A149C substitution, L373R substitution, I379V substitution, M447V substitution, Y458C substitution, K465Q substitution, D486C substitution, D489C substitution are Figure 1 The wild-type full-length amino acid sequence of the hRSV F protein before fusion is shown. For example, S46G is replaced by the wild-type hRSV F protein before fusion. Figure 1 The 46th amino acid residue of the wild-type hRSV F protein before fusion was replaced by a G amino acid residue. This mutation occurred in the F2 sequence. For example, the sequence 525 to 529 is based on the wild-type hRSV F protein before fusion. Figure 1 The RR2 sequence and the TM sequence are connected to the wild type hRSV F protein before fusion. For example, the sequence 551 to 574 is based on the wild type hRSV F protein before fusion. Figure 1 The figure shows that the wild-type hRSV F protein is connected to the C-terminus of the TM sequence before fusion.
[0125] In some embodiments, the amino acid sequence of the hRSV F protein before fusion is as shown in Seq ID NO.62, Seq ID NO.76, Seq ID NO.78, or comprises an amino acid sequence that is at least 80% identical to Seq ID NO.62, Seq ID NO.76, Seq ID NO.78, for example, it can be but is not limited to an amino acid sequence that is at least 80%, 85%, 90%, 95% or 98% identical to Seq ID NO.62, Seq ID NO.76, Seq ID NO.78.
[0126] In some embodiments, the amino acid sequence of the stabilized pre-fusion form of the hRSV F protein variant is as shown in Seq ID NO.66, or comprises an amino acid sequence that is at least 80% identical to Seq ID NO.66, for example, it can be but is not limited to an amino acid sequence that is at least 80%, 85%, 90%, 95% or 98% identical to Seq ID NO.66.
[0127] In some embodiments, the amino acid sequence of the stabilized pre-fusion form of the hRSV F protein variant is as shown in Seq ID NO.70, or comprises an amino acid sequence that is at least 80% identical to Seq ID NO.70, for example, it can be but is not limited to an amino acid sequence that is at least 80%, 85%, 90%, 95% or 98% identical to Seq ID NO.70.
[0128] In some embodiments, the amino acid sequence of the stabilized pre-fusion form of the hRSV F protein variant is as shown in Seq ID NO.64, or comprises an amino acid sequence that is at least 80% identical to Seq ID NO.64, for example, it can be but is not limited to an amino acid sequence that is at least 80%, 85%, 90%, 95% or 98% identical to Seq ID NO.64.
[0129] In some embodiments, the amino acid sequence of the stabilized pre-fusion form of the hRSV F protein variant is as shown in Seq ID NO.68, or comprises an amino acid sequence that is at least 80% identical to Seq ID NO.68, for example, it can be but is not limited to an amino acid sequence that is at least 80%, 85%, 90%, 95% or 98% identical to Seq ID NO.68.
[0130] In some embodiments, the amino acid sequence of the stabilized pre-fusion form of the hRSV F protein variant is as shown in Seq ID NO.72, or comprises an amino acid sequence that is at least 80% identical to Seq ID NO.72, for example, it can be but is not limited to an amino acid sequence that is at least 80%, 85%, 90%, 95% or 98% identical to Seq ID NO.72.
[0131] In some embodiments, the pre-fusion hRSV F protein variant includes an amino acid sequence in which at least one of the amino acids of the F2 sequence, the RR1 sequence, the RR2 sequence, the 525-529 sequence, or the 551-574 sequence is continuously or intermittently deleted.
[0132] In some embodiments, amino acids 98 to 109 of the hRSV F protein variant F2 sequence before fusion are continuously or intermittently missing at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 amino acid sequences.
[0133] In some embodiments, amino acids 137 to 144 of the RR1 sequence of the hRSV F protein variant before fusion are continuously or intermittently missing at least 1, 2, 3, 4, 5, 6, 7, or 8 amino acid sequences.
[0134] In some embodiments, amino acids 504 to 524 of the hRSV F protein variant RR2 sequence before fusion are continuously or intermittently missing at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or 21 amino acid sequences.
[0135] In some embodiments, the amino acid sequence 525-529 of the hRSV F protein variant before fusion lacks at least 1, 2, 3, 4, or 5 amino acid sequences continuously or intermittently.
[0136] In some embodiments, the amino acid sequence 551-574 of the hRSV F protein variant before fusion lacks at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 amino acid sequences continuously or intermittently.
[0137] In some embodiments, the amino acid sequence of the hRSV F protein before fusion is as shown in Seq ID NO.62, Seq ID NO.64, Seq ID NO.66, Seq ID NO.68, Seq ID NO.70, Seq ID NO.72, Seq ID NO.76, and Seq ID NO.78; and / or includes: at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 amino acid sequences are continuously or intermittently deleted from amino acids 98 to 109 of the F2 sequence, and / or at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 amino acid sequences are continuously or intermittently deleted from amino acids 137 to 144 of the RR1 sequence, and / or at least 1, 2, 3, 4, 5, 6, 7, or 8 amino acid sequences are continuously or intermittently deleted from amino acids 504 to 524 of the RR2 sequence. and / or, the amino acids in the 525-529 sequence are continuously or intermittently deleted with at least 1, 2, 3, 4, or 5 amino acids; and / or, the amino acids in the 551-574 sequence are continuously or intermittently deleted with at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 amino acids.
[0138] In some embodiments, the amino acid sequence of the hRSV F protein before fusion is as shown in Seq ID NO.62, Seq ID NO.64, Seq ID NO.66, Seq ID NO.70, Seq ID NO.76, and Seq ID NO.78; and / or includes: at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 amino acid sequences are continuously or intermittently deleted from amino acids 98 to 109 of the F2 sequence, and / or at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 amino acid sequences are continuously or intermittently deleted from amino acids 137 to 144 of the RR1 sequence, and / or at least 1, 2, 3, 4, 5, 6, 7, or 8 amino acid sequences are continuously or intermittently deleted from amino acids 504 to 524 of the RR2 sequence. and / or, the amino acids in the 525-529 sequence are continuously or intermittently deleted with at least 1, 2, 3, 4, or 5 amino acids; and / or, the amino acids in the 551-574 sequence are continuously or intermittently deleted with at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 amino acids.
[0139] In some embodiments, the amino acid sequence of the hRSV F protein before fusion is as shown in Seq ID NO.62, Seq ID NO.66, Seq ID NO.70, Seq ID NO.76, and Seq ID NO.78; and / or includes: amino acids 98 to 109 of the F2 sequence are continuously or intermittently deleted by at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 amino acid sequences, and / or, amino acids 137 to 144 of the RR1 sequence are continuously or intermittently deleted by at least 1, 2, 3, 4, 5, 6, 7, or 8 amino acid sequences, and / or, amino acids 504 to 524 of the RR2 sequence are continuously or intermittently deleted by at least 1, 2, 3, 4, 5, 6, 7, or 8 amino acids. and / or, the amino acids in the 525-529 sequence are continuously or intermittently deleted with at least 1, 2, 3, 4, or 5 amino acids; and / or, the amino acids in the 551-574 sequence are continuously or intermittently deleted with at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 amino acids.
[0140] In some embodiments, the multimerization element of the pre-fusion hRSV F protein can also be selected from the amino acid sequences shown in Seq ID NO.1-12 and Seq ID NO.14-15.
[0141] In some embodiments, the immune composition encoding human respiratory syncytial virus (hRSV) antigen is a nucleic acid immune composition; the nucleic acid immune composition comprises a nucleic acid molecule; the nucleic acid molecule comprises a DNA molecule and / or an RNA molecule.
[0142] In some embodiments, the DNA molecule comprises a linear DNA molecule and / or a circular DNA molecule.
[0143] In some embodiments, the RNA molecule comprises mRNA or circular RNA.
[0144] In some embodiments, the mRNA molecule includes an open reading frame (ORF), the nucleotide sequence of the open reading frame (ORF) is as shown in Seq ID NO.63, Seq ID NO.65, Seq ID NO.67, Seq ID NO.69, Seq ID NO.71, Seq ID NO.73, Seq ID NO.77, Seq ID NO.79, Seq ID NOs.84-103, or, comprises a nucleotide sequence that is at least 80% identical to Seq ID NO.63, Seq ID NO.65, Seq ID NO.67, Seq ID NO.69, Seq ID NO.71, Seq ID NO.73, Seq ID NO.77, Seq ID NO.79, Seq ID NOs.84-103, for example, it can be but is not limited to comprising a nucleotide sequence that is at least 80% identical to Seq ID NO.63, Seq ID NO.65, Seq ID NO.67, Seq ID NO.69, Seq ID NO.71, Seq ID NO.73, Seq ID NO.77, Seq ID NO.79, Seq ID NOs.84-103. No. 73, Seq ID No. 77, Seq ID No. 79, Seq ID Nos. 84-103 are at least 80%, 85%, 90%, 95% or 98% identical nucleotide sequences.
[0145] In some embodiments, the mRNA molecule includes an open reading frame (ORF), the nucleotide sequence of the open reading frame (ORF) is as shown in Seq ID NO.63, Seq ID NO.67, Seq ID NO.71, Seq ID NO.77, Seq ID NO.79, Seq ID NO.84-103, or, comprises a nucleotide sequence that is at least 80% identical to Seq ID NO.63, Seq ID NO.67, Seq ID NO.71, Seq ID NO.77, Seq ID NO.79, Seq ID NO.84-103, for example, it can be but is not limited to a nucleotide sequence that is at least 80%, 85%, 90%, 95% or 98% identical to Seq ID NO.63, Seq ID NO.67, Seq ID NO.71, Seq ID NO.77, Seq ID NO.79, Seq ID NO.84-103.
[0146] In some embodiments, the mRNA molecule includes an open reading frame (ORF), the nucleotide sequence of the open reading frame (ORF) is as shown in Seq ID NO.63, Seq ID NO.71, Seq ID NO.77, Seq ID NO.79, Seq ID NO.84-87, Seq ID NO.92-103, or, comprises a nucleotide sequence that is at least 80% identical to Seq ID NO.63, Seq ID NO.71, Seq ID NO.77, Seq ID NO.79, Seq ID NO.84-87, Seq ID NO.92-103, for example, it can be but is not limited to a nucleotide sequence that is at least 80%, 85%, 90%, 95% or 98% identical to Seq ID NO.63, Seq ID NO.71, Seq ID NO.77, Seq ID NO.79, Seq ID NO.84-87, Seq ID NO.92-103.
[0147] In some embodiments, the mRNA molecule includes an open reading frame (ORF), the nucleotide sequence of the open reading frame (ORF) is as shown in Seq ID NO.63, Seq ID NO.77, Seq ID NO.79, Seq ID NO.84-87, Seq ID NO.96-103, or, comprises a nucleotide sequence that is at least 80% identical to Seq ID NO.63, Seq ID NO.77, Seq ID NO.79, Seq ID NO.84-87, Seq ID NO.96-103, for example, it can be but is not limited to a nucleotide sequence that is at least 80%, 85%, 90%, 95% or 98% identical to Seq ID NO.63, Seq ID NO.77, Seq ID NO.79, Seq ID NO.84-87, Seq ID NO.96-103.
[0148] In some embodiments, the mRNA molecule includes an open reading frame (ORF), the nucleotide sequence of the open reading frame (ORF) is as shown in Seq ID NO.63, Seq ID NO.84-87, or, comprises a nucleotide sequence that is at least 80% identical to Seq ID NO.63, Seq ID NO.84-87, for example, it can be but is not limited to a nucleotide sequence that is at least 80%, 85%, 90%, 95% or 98% identical to Seq ID NO.63, SeqID NO.84-87.
[0149] In some embodiments, the mRNA molecule includes an open reading frame (ORF), the nucleotide sequence of the open reading frame (ORF) is as shown in Seq ID NO.63, or, comprises a nucleotide sequence that is at least 80% identical to Seq ID NO.63, for example, it can be but is not limited to a nucleotide sequence that is at least 80%, 85%, 90%, 95% or 98% identical to Seq ID NO.63.
[0150] In some embodiments, the mRNA molecule includes an open reading frame (ORF), the nucleotide sequence of the open reading frame (ORF) is as shown in Seq ID NO.77, Seq ID NO.96-99, or, comprises a nucleotide sequence that is at least 80% identical to Seq ID NO.77, Seq ID NO.96-99, for example, it can be but is not limited to a nucleotide sequence that is at least 80%, 85%, 90%, 95% or 98% identical to Seq ID NO.77, SeqID NO.96-99.
[0151] In some embodiments, the mRNA molecule includes an open reading frame (ORF), the nucleotide sequence of the open reading frame (ORF) is as shown in Seq ID NO.77, or, comprises a nucleotide sequence that is at least 80% identical to Seq ID NO.77, for example, it can be but is not limited to a nucleotide sequence that is at least 80%, 85%, 90%, 95% or 98% identical to Seq ID NO.77.
[0152] In some embodiments, the mRNA molecule includes an open reading frame (ORF), the nucleotide sequence of the open reading frame (ORF) is as shown in Seq ID NO.79, Seq ID NO.100-103, or, comprises a nucleotide sequence that is at least 80% identical to Seq ID NO.79, Seq ID NO.100-103, for example, it can be but is not limited to a nucleotide sequence that is at least 80%, 85%, 90%, 95% or 98% identical to Seq ID NO.79, Seq ID NO.100-103.
[0153] In some embodiments, the mRNA molecule includes an open reading frame (ORF), the nucleotide sequence of the open reading frame (ORF) is as shown in Seq ID NO.79, or, comprises a nucleotide sequence that is at least 80% identical to Seq ID NO.79, for example, it can be but is not limited to a nucleotide sequence that is at least 80%, 85%, 90%, 95% or 98% identical to Seq ID NO.79.
[0154] In some embodiments, the mRNA molecule includes an open reading frame (ORF), the nucleotide sequence of the open reading frame (ORF) is as shown in Seq ID NO.65, or, comprises a nucleotide sequence that is at least 80% identical to Seq ID NO.65, for example, it can be but is not limited to a nucleotide sequence that is at least 80%, 85%, 90%, 95% or 98% identical to Seq ID NO.65.
[0155] In some embodiments, the mRNA molecule includes an open reading frame (ORF), the nucleotide sequence of the open reading frame (ORF) is as shown in Seq ID NO.67, Seq ID NO.88-91, or, comprises a nucleotide sequence that is at least 80% identical to Seq ID NO.67, Seq ID NO.88-91, for example, it can be but is not limited to a nucleotide sequence that is at least 80%, 85%, 90%, 95% or 98% identical to Seq ID NO.67, SeqID NO.88-91.
[0156] In some embodiments, the mRNA molecule includes an open reading frame (ORF), the nucleotide sequence of the open reading frame (ORF) is as shown in Seq ID NO.67, or, comprises a nucleotide sequence that is at least 80% identical to Seq ID NO.67, for example, it can be but is not limited to a nucleotide sequence that is at least 80%, 85%, 90%, 95% or 98% identical to Seq ID NO.67.
[0157] In some embodiments, the mRNA molecule includes an open reading frame (ORF), the nucleotide sequence of the open reading frame (ORF) is as shown in Seq ID NO.69, or, comprises a nucleotide sequence that is at least 80% identical to Seq ID NO.69, for example, it can be but is not limited to a nucleotide sequence that is at least 80%, 85%, 90%, 95% or 98% identical to Seq ID NO.69.
[0158] In some embodiments, the mRNA molecule includes an open reading frame (ORF), the nucleotide sequence of the open reading frame (ORF) is as shown in Seq ID NO.71, Seq ID NO.92-95, or, comprises a nucleotide sequence that is at least 80% identical to Seq ID NO.71, Seq ID NO.92-95, for example, it can be but is not limited to a nucleotide sequence that is at least 80%, 85%, 90%, 95% or 98% identical to Seq ID NO.71, SeqID NO.92-95.
[0159] In some embodiments, the mRNA molecule includes an open reading frame (ORF), the nucleotide sequence of the open reading frame (ORF) is as shown in Seq ID NO.71, or, comprises a nucleotide sequence that is at least 80% identical to Seq ID NO.71, for example, it can be but is not limited to a nucleotide sequence that is at least 80%, 85%, 90%, 95% or 98% identical to Seq ID NO.71.
[0160] In some embodiments, the mRNA molecule includes an open reading frame (ORF), the nucleotide sequence of the open reading frame (ORF) is as shown in Seq ID NO.73, or, comprises a nucleotide sequence that is at least 80% identical to Seq ID NO.73, for example, it can be but is not limited to a nucleotide sequence that is at least 80%, 85%, 90%, 95% or 98% identical to Seq ID NO.73.
[0161] In some embodiments, the nucleotide sequence of the dimerization element is as shown in Seq ID NO.36, Seq ID NO.42, or, the encoded amino acid sequence after sequence optimization is as shown in Seq ID NO.1-2; the nucleotide sequence of the trimerization is as shown in Seq ID NO.37-40, Seq ID NO.43-46, Seq ID NO.13, or, the encoded amino acid sequence after sequence optimization is as shown in Seq ID NO.3-12; the nucleotide sequence of the tetramerization element is as shown in Seq ID NO.41, Seq ID NO.47, and the encoded amino acid sequence after sequence optimization is as shown in Seq ID NO.14-15.
[0162] Furthermore, in some embodiments, the nucleotide sequence of the multimerization element in the open reading frame (ORF) can also be as shown in Seq ID NO.36-47 and Seq ID NO.13.
[0163] In some embodiments, nucleic acid molecules can optimize mRNA sequences by sequence optimization means to improve properties related to expression efficacy after in vivo administration: for example, improving mRNA stability, increasing translation efficacy in target tissues, reducing the number of truncated proteins expressed, improving the folding of expressed proteins or preventing their misfolding, reducing the toxicity of expression products, reducing cell death caused by expression products, increasing and / or reducing protein aggregation, and obtaining mRNA with improved properties. The purpose of sequence optimization also includes: optimizing the formulation and delivery characteristics of nucleic acid-based therapeutic agents while maintaining structural and functional integrity; overcoming expression thresholds; increasing expression rates; half-life and / or protein concentrations; optimizing protein localization; and avoiding adverse biological responses such as immune responses and / or degradation pathways. Sequence optimization approaches include: (1) codon optimization based on codon frequencies in specific organs and / or host organisms to ensure proper folding and appropriate expression; (2) adjustment of G / C content to increase mRNA stability or reduce secondary structure; (3) minimization of tandemly repeated codons or base runs that may impair gene construction or expression; (4) customization of transcription and translation control regions; and (5) reduction or elimination of problematic secondary structures within polynucleotides.
[0164] The "sequence identity" between two nucleotide sequences indicates the percentage of identical nucleotides between the sequences. The "sequence identity" between two amino acid sequences indicates the percentage of identical amino acids between the sequences.
[0165] The term "% identity" or similar terms refers to the percentage of identical nucleotides or amino acids between the sequences to be compared under optimal alignment. This percentage is purely statistical, and the differences between the two sequences may (but are not necessarily) randomly distributed over the entire length of the sequences to be compared. The comparison of two sequences is usually performed by comparing the sequences with respect to fragments or "comparison windows" after optimal alignment to identify local regions of corresponding sequences.
[0166] In some embodiments, based on the mRNA open reading frame sequence provided, a person of ordinary skill in the art will be able to obtain the corresponding circular RNA open reading frame sequence, and according to the contents of the open literature such as CN202180048567.4, a circular RNA complete sequence capable of encoding the same amino acid sequence is prepared. In some embodiments, based on the mRNA sequence provided, a person of ordinary skill in the art will be able to obtain the corresponding DNA sequence (e.g., uracil is converted to thymine). Similarly, based on the DNA sequence provided, a person of ordinary skill in the art will obtain the corresponding RNA sequence (e.g., thymine is converted to uracil). In some embodiments, based on the RNA or DNA sequence provided, a person of ordinary skill in the art will be able to obtain the corresponding amino acid sequence.
[0167] The open reading frame (ORF) described in the present disclosure is a continuous stretch of DNA or RNA that begins with a start codon (such as ATG or AUG) and ends with a stop codon (such as TAA, TAG or TGA, or UAA, UAG or UGA).
[0168] In some embodiments, the mRNA described in the present disclosure consists of a sequence including a 5' cap, a 5' UTR, an ORF, a 3' UTR and a 3' poly (A) tail in sequence from the 5' end to the 3' end.
[0169] The 5' untranslated region (UTR) described in the present disclosure refers to a sequence located immediately upstream (i.e., 5') of the start codon (i.e., the first codon of the mRNA transcript translated by the ribosome) of an mRNA that does not encode a polypeptide. When an RNA transcript is produced, the 5'UTR may include a promoter sequence. Such promoter sequences are known in the art. The RNA sequence of the 5'UTR is shown in one of Seq ID NO. 16, Seq ID NO. 17, or Seq ID NO. 18, or a 5'UTR sequence disclosed before the filing date of the present disclosure may also be introduced into the present disclosure.
[0170] The 3' untranslated region (UTR) described in the present disclosure refers to a sequence located downstream of the stop codon of an mRNA that does not encode a polypeptide. The RNA sequence of the 3'UTR is shown in one of Seq ID NO.19, Seq ID NO.20 or Seq ID NO.21, or a 3'UTR sequence disclosed before the filing date of the present disclosure can also be introduced into the present disclosure.
[0171] The poly (A) tail described in the present disclosure is a sequence located downstream of the 3'UTR of mRNA containing multiple consecutive adenosine monophosphates. The poly (A) tail may contain 10 to 300 adenosine monophosphates. In cells and / or in vivo, the poly (A) tail is used to protect mRNA from enzymatic degradation and to help transcription termination, and / or mRNA export and translation from the nucleus.
[0172] In some embodiments, the mRNA molecule comprises a self-replicating mRNA molecule or a non-self-replicating mRNA molecule.
[0173] In some embodiments, the mRNA described in the present disclosure is a self-replicating mRNA, which carries a sequence capable of expressing RNA polymerase (RNA-dependent RNA polymerase, RdRP). Specifically, the sequence design content of self-replicating mRNA in Chinese patent CN202110424124.2 is introduced into the present disclosure.
[0174] In some embodiments, the immunological composition comprises a delivery formulation.
[0175] In some embodiments, the delivery formulation comprises lipid nanoparticles or cationic liposomes.
[0176] In some embodiments, the components of the lipid nanoparticles include at least one of a protonatable cationic lipid, a structural lipid, a helper lipid, and a surfactant.
[0177] In some embodiments, the components of the lipid nanoparticles include, by weight: 40 to 60 parts of protonable cationic lipids, 20 to 40 parts of structural lipids, 10 to 30 parts of auxiliary lipids, and 0.5 to 5 parts of surfactants.
[0178] In some embodiments, the protonatable cationic lipid is selected from at least one of Dlin-MC3-DMA, DODMA, C12-200, and DlinDMA.
[0179] In some embodiments, the structured lipid comprises cholesterol and / or a cholesterol derivative.
[0180] In some embodiments, the helper lipid includes at least one of DSPC, DOPE, DOPC, DOPG, and DOPS.
[0181] In some embodiments, the surfactant includes at least one of PEG-DMG, PEG-DSPE, and TPGS.
[0182] In some embodiments, the liposome nanoparticles include, by molar percentage, 20% to 50% of cationic lipids, such as but not limited to 20%, 25%, 30%, 35%, 40%, 45% or 50%; 20% to 50% of DOPG, such as but not limited to 20%, 25%, 30%, 35%, 40%, 45% or 50%; 5% to 20% of cholesterol, such as but not limited to 5%, 10%, 15% or 20%; and 1% to 5% of PEG-DMG, such as but not limited to 1%, 2%, 3%, 4% or 5%.
[0183] In some embodiments, the liposome nanoparticles include, by mole percentage, 20% to 50% of cationic lipids, such as but not limited to 20%, 25%, 30%, 35%, 40%, 45% or 50%; 20% to 50% of DSCP, such as but not limited to 20%, 25%, 30%, 35%, 40%, 45% or 50%; 5% to 20% of cholesterol, such as but not limited to 5%, 10%, 15% or 20%; and 1% to 5% of PEG-DMG, such as but not limited to 1%, 2%, 3%, 4% or 5%.
[0184] In some embodiments, the liposome nanoparticles include 50% Dlin-MC3-DMA, 10% DOPG, 38.5% cholesterol, and 1.5% PEG-DMG by mole percentage.
[0185] In some embodiments, the liposome nanoparticles include 50% Dlin-MC3-DMA, 10% DSCP, 38.5% cholesterol, and 1.5% PEG-DMG by mole percentage.
[0186] In some embodiments, the present disclosure provides a method for preparing an immune composition as described in any of the aforementioned embodiments, characterized in that it includes: mixing the mRNA and a delivery preparation to form an immune composition; the delivery preparation includes lipid nanoparticles or cationic liposomes.
[0187] In some embodiments, in the method for preparing the immune composition, mRNA is dissolved in a buffer to obtain an aqueous phase, each lipid component of the liposome nanoparticle is measured and dissolved in an organic solvent to obtain an organic phase, and the aqueous phase and the organic phase are mixed and then the organic phase is removed to obtain the immune composition.
[0188] In some embodiments, the volume ratio of the aqueous phase to the organic phase is 1:2-4, preferably 1:3.
[0189] In some embodiments, the buffer comprises citrate buffer or sodium acetate, preferably citrate buffer.
[0190] In some embodiments, the pH of the buffer is 3-7, preferably 4.
[0191] In some embodiments, the concentration of mRNA in the aqueous phase is 0.05 mg / mL to 0.5 mg / mL, preferably 0.1 mg / mL.
[0192] In some embodiments, the organic solvent is selected from C1-C4 low-carbon alcohols, preferably anhydrous ethanol.
[0193] In some embodiments, the concentration of the lipid component in the organic phase is 5 mg / mL to 7 mg / mL, preferably 6 mg / mL.
[0194] In some embodiments, microfluidics is used to mix the aqueous and organic phases and tangential flow is used to filter the organic solvent;
[0195] Preferably, the microfluidic flow rate is >3 ml / min, more preferably 12 mL / min.
[0196] In some embodiments, the step of concentration is further included after mixing, wherein the final concentration of the mRNA is 50 μg / mL to 200 μg / mL, preferably 100 μg / mL.
[0197] In some embodiments, the diameter of the lipid nanoparticle is less than about 200 nm. In some embodiments, the diameter of the lipid nanoparticle is less than about 150 nm. In some embodiments, the diameter of the lipid nanoparticle is less than 100 nm. In some embodiments, the diameter of the lipid nanoparticle is about 55 nm to about 90 nm.
[0198] In some embodiments, the immune composition comprising human respiratory syncytial virus (hRSV) antigen is a polypeptide immune composition. The polypeptide immune composition is an immune composition prepared by chemical synthesis technology or genetic engineering technology according to the amino acid sequence of a known or predicted segment of an antigenic epitope in the human respiratory syncytial virus antigen gene. In some embodiments, the polypeptide immune composition described in the present disclosure is an immune composition prepared by chemical synthesis technology according to the amino acid sequence of the hRSVF protein before fusion of human respiratory syncytial virus, combined with artificial mutation and transformation. In some embodiments, the polypeptide immune composition described in the present disclosure is obtained after fermentation according to the amino acid sequence of the hRSVF protein before fusion of human respiratory syncytial virus, combined with artificial mutation and transformation, and then by genetic engineering technology (such as constructing genetically engineered bacteria by means of genetic engineering technology, etc.).
[0199] In some embodiments, the polypeptide immune composition comprises a pre-fusion hRSV F protein, and the amino acid sequence of the pre-fusion hRSV F protein is as shown in Seq ID NO.62, Seq ID NO.64, Seq ID NO.66, Seq ID NO.68, Seq ID NO.70, Seq ID NO.72, Seq ID NO.76, Seq ID NO.77, Seq ID NO.78, Seq ID NO.79, Seq ID NO.80, Seq ID NO.81, Seq ID NO.82, Seq ID NO.83, Seq ID NO.84, Seq ID NO.85, Seq ID NO.86, Seq ID NO.87, Seq ID NO.88, Seq ID NO.89, Seq ID NO.90, Seq ID NO.91, Seq ID NO.92, Seq ID NO.93, Seq ID NO.94, Seq ID NO.95, Seq ID NO.96, Se IDNO.78; and / or including: at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 amino acid sequences of amino acids at positions 98 to 109 of the F2 sequence are continuously or intermittently deleted, and / or, at least 1, 2, 3, 4, 5, 6, 7, 8 amino acid sequences of amino acids at positions 137 to 144 of the RR1 sequence are continuously or intermittently deleted, and / or, at least 1, 2, 3, 4, 5, 6, 7, 8 amino acid sequences of amino acids at positions 504 to 524 of the RR2 sequence are continuously or intermittently deleted. 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 amino acid sequences; and / or, the amino acids in the 525-529 sequence are continuously or intermittently deleted by at least 1, 2, 3, 4, 5 amino acid sequences; and / or, the amino acids in the 551-574 sequence are continuously or intermittently deleted by at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 amino acid sequences.
[0200] In some embodiments, the viral immune composition described in the present disclosure carries the human respiratory syncytial virus antigen hRSV F protein gene into the human body through harmless microorganisms, inducing the body's immune system to make an immune response. Important viruses used in induced cellular immunity tests include variants of bovine disease virus, polio virus, etc.
[0201] In some embodiments, the present disclosure provides an isolated mRNA, characterized in that the nucleic acid sequence of the coding region of the mRNA encodes a pre-fusion hRSV F protein, and the amino acid sequence of the pre-fusion hRSV F protein includes a TM sequence and a multimerization element; preferably, the amino acid sequence of the multimerization element is as shown in Seq ID NO.1-12, Seq ID NO.14-15; preferably, the amino acid sequence of the multimerization element is as shown in one of Seq ID NO.7 and Seq ID NO.12.
[0202] In some embodiments, in the isolated mRNA provided by the present disclosure, the P27 sequence of the hRSV F protein before fusion is replaced with a GS sequence; preferably, the GS sequence comprises (GnS)m, (GGGGS)o, GGSGGGGSGG, GGSGGGGG, GSGSGSGS, (Gly)p, (EAAAK)q, such as Seq ID NO.48-61, Seq ID NO.74 (wherein n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15 or 20; m is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15 or 20; o is an integer from 1 to 5; p is an integer from 1 to 40; q is an integer from 1 to 5); preferably, the GS sequence amino acid sequence is as shown in Seq ID NO.74.
[0203] In some embodiments, the isolated mRNA provided by the present disclosure, the amino acid sequence of the hRSV F protein before fusion includes at least one of S46G substitution, N67I substitution, E92D substitution, P102A substitution, A149C substitution, S155C substitution, S190F substitution, V207L substitution, S290C substitution, L373R substitution, S215P substitution, I379V substitution, M447V substitution, Y458C substitution, K465Q substitution, D486C substitution, and D489C substitution.
[0204] In some embodiments, the isolated mRNA provided by the present disclosure, the amino acid sequence of the pre-fusion hRSV F protein includes at least one of an S155C substitution, an S190F substitution, a V207L substitution, an S290C substitution, a D486C substitution, and a D489C substitution.
[0205] In some embodiments, the isolated mRNA provided by the present disclosure, the amino acid sequence of the pre-fusion hRSV F protein includes at least one of an S155C substitution, an S190F substitution, a V207L substitution, an S290C substitution, and / or the P27 sequence of the pre-fusion hRSV F protein is replaced with a GS sequence.
[0206] In some embodiments, the isolated mRNA provided by the present disclosure, the amino acid sequence of the hRSV F protein before fusion includes S155C substitution, S190F substitution, V207L substitution, S290C substitution; the P27 sequence of the hRSV F protein before fusion is replaced with the GS sequence shown in Seq ID NO.74; the hRSV F protein before fusion includes a multimerization element as shown in one of Seq ID NO.7 and Seq ID NO.12.
[0207] In some embodiments, the isolated mRNA provided by the present disclosure, the amino acid sequence of the hRSV F protein before fusion includes S155C substitution, S190F substitution, V207L substitution, S290C substitution; the P27 sequence of the hRSV F protein before fusion is replaced with the GS sequence as shown in Seq ID NO.74; the hRSV F protein before fusion includes a multimerization element as shown in one of Seq ID NO.7 and Seq ID NO.12; the amino acid sequence of the hRSV F protein before fusion also includes at least one of S46G substitution, N67I substitution, E92D substitution, P102A substitution, A149C substitution, L373R substitution, S215P substitution, I379V substitution, M447V substitution, Y458C substitution, K465Q substitution, D486C substitution, and D489C substitution.
[0208] In some embodiments, the isolated mRNA provided by the present disclosure, the amino acid sequence of the pre-fusion hRSV F protein includes at least one of an S155C substitution, an S190F substitution, a V207L substitution, an S290C substitution, a D486C substitution, and a D489C substitution, and / or the P27 sequence of the pre-fusion hRSV F protein is replaced with a GS sequence.
[0209] In some embodiments, the isolated mRNA provided by the present disclosure, the amino acid sequence of the hRSV F protein before fusion includes S155C substitution, S190F substitution, V207L substitution, S290C substitution, D486C substitution, D489C substitution, the P27 sequence of the hRSV F protein before fusion is replaced with the GS sequence shown in Seq ID NO.74, and the hRSV F protein before fusion includes a multimerization element as shown in one of Seq ID NO.7 and Seq ID NO.12.
[0210] In some embodiments, the isolated mRNA provided by the present disclosure, the amino acid sequence of the hRSV F protein before fusion includes S155C substitution, S190F substitution, V207L substitution, S290C substitution, D486C substitution, D489C substitution, the P27 sequence of the hRSV F protein before fusion is replaced with the GS sequence as shown in Seq ID NO.74, and the hRSV F protein before fusion includes a multimerization element as shown in one of Seq ID NO.7 and Seq ID NO.12; the amino acid sequence of the hRSV F protein before fusion also includes at least one of S46G substitution, N67I substitution, E92D substitution, P102A substitution, A149C substitution, L373R substitution, S215P substitution, I379V substitution, M447V substitution, Y458C substitution, and K465Q substitution.
[0211] In some embodiments, the isolated mRNA provided by the present disclosure, the pre-fusion hRSV F protein variant includes an amino acid sequence in which at least one of the amino acids of the F2 sequence, the RR1 sequence, the RR2 sequence, the 525-529 sequence, or the 551-574 sequence is continuously or intermittently deleted.
[0212] In some embodiments, the isolated mRNA provided by the present disclosure, the amino acid sequence of the pre-fusion hRSV F protein is shown as Seq ID NO.62, Seq ID NO.64, Seq ID NO.66, Seq ID NO.68, Seq ID NO.70, Seq ID NO.72, Seq ID NO.76, and Seq ID NO.78.
[0213] In some embodiments, the isolated mRNA provided by the present disclosure has an amino acid sequence of the pre-fusion hRSV F protein as shown in Seq ID NO.62, Seq ID NO.64, Seq ID NO.66, Seq ID NO.70, Seq ID NO.76, and Seq ID NO.78.
[0214] In some embodiments, the isolated mRNA provided by the present disclosure has an amino acid sequence of the pre-fusion hRSV F protein as shown in Seq ID NO.62, Seq ID NO.66, Seq ID NO.70, Seq ID NO.76, and Seq ID NO.78.
[0215] In some embodiments, in the isolated mRNA provided by the present disclosure, the multimerization element of the pre-fusion hRSV F protein can also be selected from the amino acid sequences shown in Seq ID NO.1-12 and Seq ID NO.14-15.
[0216] In some embodiments, the isolated mRNA includes an open reading frame (ORF), the nucleotide sequence of the open reading frame (ORF) is as shown in Seq ID NO.63, Seq ID NO.65, Seq ID NO.67, Seq ID NO.69, Seq ID NO.71, Seq ID NO.73, Seq ID NO.77, Seq ID NO.79, Seq ID NO.84-103, or, comprises a nucleotide sequence that is at least 80% identical to Seq ID NO.63, Seq ID NO.77, Seq ID NO.79, Seq ID NO.84-87, Seq ID NO.96-103, for example, it can be but is not limited to a nucleotide sequence that is at least 80%, 85%, 90%, 95% or 98% identical to Seq ID NO.63, Seq ID NO.77, Seq ID NO.79, Seq ID NO.84-87, Seq ID NO.96-103.
[0217] In some embodiments, the isolated mRNA includes an open reading frame (ORF), the nucleotide sequence of the open reading frame (ORF) is as shown in Seq ID NO.63, Seq ID NO.67, Seq ID NO.71, Seq ID NO.77, Seq ID NO.79, Seq ID NO.84-103, or, comprises a nucleotide sequence that is at least 80% identical to Seq ID NO.63, Seq ID NO.67, Seq ID NO.71, Seq ID NO.77, Seq ID NO.79, Seq ID NO.84-103, for example, it can be but is not limited to a nucleotide sequence that is at least 80%, 85%, 90%, 95% or 98% identical to Seq ID NO.63, Seq ID NO.67, Seq ID NO.71, Seq ID NO.77, Seq ID NO.79, Seq ID NO.84-103.
[0218] In some embodiments, the isolated mRNA includes an open reading frame (ORF), the nucleotide sequence of the open reading frame (ORF) is as shown in Seq ID NO.63, Seq ID NO.71, Seq ID NO.77, Seq ID NO.79, Seq ID NO.84-87, Seq ID NO.92-103, or, comprises a nucleotide sequence that is at least 80% identical to Seq ID NO.63, Seq ID NO.71, Seq ID NO.77, Seq ID NO.79, Seq ID NO.84-87, Seq ID NO.92-103, for example, it can be but is not limited to a nucleotide sequence that is at least 80%, 85%, 90%, 95% or 98% identical to Seq ID NO.63, Seq ID NO.71, Seq ID NO.77, Seq ID NO.79, Seq ID NO.84-87, Seq ID NO.92-103.
[0219] In some embodiments, the isolated mRNA includes an open reading frame (ORF), the nucleotide sequence of the open reading frame (ORF) is as shown in Seq ID NO.63, Seq ID NO.77, Seq ID NO.79, Seq ID NO.84-87, Seq ID NO.96-103, or, comprises a nucleotide sequence that is at least 80% identical to Seq ID NO.63, Seq ID NO.77, Seq ID NO.79, Seq ID NO.84-87, Seq ID NO.96-103, for example, it can be but is not limited to a nucleotide sequence that is at least 80%, 85%, 90%, 95% or 98% identical to Seq ID NO.63, Seq ID NO.77, Seq ID NO.79, Seq ID NO.84-87, Seq ID NO.96-103.
[0220] In some embodiments, the isolated mRNA includes an open reading frame (ORF), the nucleotide sequence of the open reading frame (ORF) is as shown in Seq ID NO.63, Seq ID NO.84-87, or, comprises a nucleotide sequence that is at least 80% identical to Seq ID NO.63, Seq ID NO.84-87, for example, it can be but is not limited to a nucleotide sequence that is at least 80%, 85%, 90%, 95% or 98% identical to Seq ID NO.63, Seq ID NO.84-87.
[0221] In some embodiments, the isolated mRNA includes an open reading frame (ORF), the nucleotide sequence of the open reading frame (ORF) is as shown in Seq ID NO.63, or, comprises a nucleotide sequence that is at least 80% identical to Seq ID NO.63, for example, it can be but is not limited to a nucleotide sequence that is at least 80%, 85%, 90%, 95% or 98% identical to Seq ID NO.63.
[0222] In some embodiments, the isolated mRNA includes an open reading frame (ORF), the nucleotide sequence of the open reading frame (ORF) is as shown in Seq ID NO.77, Seq ID NO.96-99, or, comprises a nucleotide sequence that is at least 80% identical to Seq ID NO.77, Seq ID NO.96-99, for example, it can be but is not limited to a nucleotide sequence that is at least 80%, 85%, 90%, 95% or 98% identical to Seq ID NO.77, Seq ID NO.96-99.
[0223] In some embodiments, the isolated mRNA includes an open reading frame (ORF), the nucleotide sequence of the open reading frame (ORF) is as shown in Seq ID NO.77, or, comprises a nucleotide sequence that is at least 80% identical to Seq ID NO.77, for example, it can be but is not limited to a nucleotide sequence that is at least 80%, 85%, 90%, 95% or 98% identical to Seq ID NO.77.
[0224] In some embodiments, the isolated mRNA includes an open reading frame (ORF), the nucleotide sequence of the open reading frame (ORF) is as shown in Seq ID NO.79, Seq ID NO.100-103, or, comprises a nucleotide sequence that is at least 80% identical to Seq ID NO.79, Seq ID NO.100-103, for example, it can be but is not limited to a nucleotide sequence that is at least 80%, 85%, 90%, 95% or 98% identical to Seq ID NO.79, Seq ID NO.100-103.
[0225] In some embodiments, the isolated mRNA includes an open reading frame (ORF), the nucleotide sequence of the open reading frame (ORF) is as shown in Seq ID NO.79, or, comprises a nucleotide sequence that is at least 80% identical to Seq ID NO.79, for example, it can be but is not limited to a nucleotide sequence that is at least 80%, 85%, 90%, 95% or 98% identical to Seq ID NO.79.
[0226] In some embodiments, the isolated mRNA includes an open reading frame (ORF), the nucleotide sequence of the open reading frame (ORF) is as shown in Seq ID NO.65, or, comprises a nucleotide sequence that is at least 80% identical to Seq ID NO.65, for example, it can be but is not limited to a nucleotide sequence that is at least 80%, 85%, 90%, 95% or 98% identical to Seq ID NO.65.
[0227] In some embodiments, the isolated mRNA includes an open reading frame (ORF), the nucleotide sequence of the open reading frame (ORF) is as shown in Seq ID NO.67, Seq ID NO.88-91, or, comprises a nucleotide sequence that is at least 80% identical to Seq ID NO.67, Seq ID NO.88-91, for example, it can be but is not limited to a nucleotide sequence that is at least 80%, 85%, 90%, 95% or 98% identical to Seq ID NO.67, Seq ID NO.88-91.
[0228] In some embodiments, the isolated mRNA includes an open reading frame (ORF), the nucleotide sequence of the open reading frame (ORF) is as shown in Seq ID NO.67, or comprises a nucleotide sequence that is at least 80% identical to Seq ID NO.67, for example, it can be but is not limited to a nucleotide sequence that is at least 80%, 85%, 90%, 95% or 98% identical to Seq ID NO.67.
[0229] In some embodiments, the isolated mRNA includes an open reading frame (ORF), the nucleotide sequence of the open reading frame (ORF) is as shown in Seq ID NO.69, or, comprises a nucleotide sequence that is at least 80% identical to Seq ID NO.69, for example, it can be but is not limited to a nucleotide sequence that is at least 80%, 85%, 90%, 95% or 98% identical to Seq ID NO.69.
[0230] In some embodiments, the isolated mRNA includes an open reading frame (ORF), the nucleotide sequence of the open reading frame (ORF) is as shown in Seq ID NO.71, Seq ID NO.92-95, or, comprises a nucleotide sequence that is at least 80% identical to Seq ID NO.71, Seq ID NO.92-95, for example, it can be but is not limited to a nucleotide sequence that is at least 80%, 85%, 90%, 95% or 98% identical to Seq ID NO.71, Seq ID NO.92-95.
[0231] In some embodiments, the isolated mRNA includes an open reading frame (ORF), the nucleotide sequence of the open reading frame (ORF) is as shown in Seq ID NO.71, or, comprises a nucleotide sequence that is at least 80% identical to Seq ID NO.71, for example, it can be but is not limited to a nucleotide sequence that is at least 80%, 85%, 90%, 95% or 98% identical to Seq ID NO.71.
[0232] In some embodiments, the isolated mRNA includes an open reading frame (ORF), the nucleotide sequence of the open reading frame (ORF) is as shown in Seq ID NO.73, or, comprises a nucleotide sequence that is at least 80% identical to Seq ID NO.73, for example, it can be but is not limited to a nucleotide sequence that is at least 80%, 85%, 90%, 95% or 98% identical to Seq ID NO.73.
[0233] Furthermore, in some embodiments, the nucleotide sequence of the multimerization element in the open reading frame (ORF) of the isolated mRNA can also be as shown in Seq ID NO.36-47 and Seq ID NO.13.
[0234] In some embodiments, the present disclosure provides an isolated DNA, characterized in that the DNA is obtained by reverse transcription of the mRNA or mRNA molecule nucleic acid isolated as described in any of the above items, or the DNA is a sequence or mRNA molecule that can transcribe the mRNA isolated as described in any of the above items.
[0235] In some embodiments, the isolated DNA is isolated linear DNA or isolated circular DNA.
[0236] In some embodiments, the present disclosure provides a biological material, comprising any one of an expression cassette, a vector, an engineered bacterium or a cell line, wherein the biological material contains or expresses the mRNA isolated as described in any of the foregoing or the DNA isolated as described in any of the foregoing.
[0237] In some embodiments, the present disclosure provides a method comprising administering to a subject an effective amount of at least one of the immune composition described in any of the foregoing, the isolated mRNA described in any of the foregoing, the isolated DNA described in any of the foregoing, or the biological material described in any of the foregoing to induce a neutralizing antibody response against human syncytial virus in the subject.
[0238] In some embodiments, the method comprises administering to the subject at least twice an effective amount of at least one of the immunological composition described in any of the preceding claims, the isolated mRNA described in any of the preceding claims, the isolated DNA described in any of the preceding claims, or the biological material described in any of the preceding claims.
[0239] In some embodiments, the time interval between the first administration and the second administration in the at least two administrations is no less than 14 days.
[0240] In some embodiments, the subject is immunocompromised; in some embodiments, the subject is no older than 5 years old or no younger than 65 years old.
[0241] In some embodiments, the effective amount described in the present disclosure is as low as 40 μg, 30 μg, 25 μg, 20 μg, 15 μg, 10 μg, 5 μg, 3 μg or 1 μg of any of the aforementioned immune compositions, any of the aforementioned isolated mRNA or any of the aforementioned isolated DNA, or any of the aforementioned biological materials.
[0242] Example 1: Process for preparing LNP from RNA
[0243] A lipid nanoparticle comprising RNA encoding a respiratory syncytial virus antigen, wherein the lipid nanoparticle comprises, by mole percentage, 50% of Dlin-MC3-DMA, 20% of DOPG, 29% of cholesterol and 1% of PEG-DMG.
[0244] The preparation method is as follows:
[0245] (a) RNA was dissolved in a pH 4 citrate buffer and the concentration was adjusted to 0.1 mg / ml to obtain an aqueous phase.
[0246] (b) Dissolving Dlin-MC3-DMA, DOPG, cholesterol and PEG-DMG in anhydrous ethanol according to the formulated amounts, adjusting the concentration of the lipid component in the organic phase to 6 mg / mL, and obtaining an organic phase.
[0247] (c) The aqueous phase of step (a) and the organic phase of step (b) are mixed in a volume ratio of 1:3 using a microfluidic device at a flow rate of 12 mL / min, and the mixed solution is immediately diluted 100 times with a pH 7.4 PBS solution, and the ethanol component in the solution is removed by tangential flow filtration (TFF), and then concentrated to a concentration of 55 ug / ml of mRNA in the system to obtain lipid nanoparticles containing RNA encoding respiratory syncytial virus antigen.
[0248] Example 2
[0249] Using luciferase as a reporter gene, the formulations of different vaccine vectors were studied by in vivo fluorescence imaging technology (as shown in Table 1 below.
[0250] Table 1
[0251]
[0252] "MC3" refers to Dlin-MC3-DMA, "+": luciferase expression in mice was detected by the small animal in vivo fluorescence phase system after administration) The efficiency of delivering mRNA encoding the luciferase gene in mice, and detecting the physical and chemical indicators of different composite preparations (see Example 1 for preparation methods), the results are shown in Table 1. Through research, it was found that increasing the mass ratio of lipids to mRNA is beneficial to increasing the encapsulation rate of mRNA in lipid nanoparticles so that it has higher stability. In addition, moderately increasing the content of polyethylene glycol (PEG) in the formula is beneficial to improving the expression efficiency of mRNA in vivo. Therefore, considering the mRNA encapsulation rate and the efficiency of mRNA delivery in vivo, formulas 3 and 4 were selected for subsequent mRNA vaccine research.
[0253] Example 3
[0254] The ability of cationic lipid nanoparticles of different formulations to encapsulate mRNA encoding luciferase and the particle size data of the formed nanoparticles are shown in Table 2. Several formulations can compress luciferase mRNA into nanoparticles with a particle size of less than 100 nm and a net neutral surface potential, and can encapsulate at least 50% of the mRNA, so they can all have a certain in vivo delivery effect. "MC3" refers to Dlin-MC3-DMA.
[0255] Table 2
[0256]
[0257] Example 4
[0258] BALB / c mice (female, 5-6 weeks old, average body weight 20-25 g, purchased from Zhuhai Baishitong Biotechnology Co., Ltd.) were selected for vaccine immunogenicity evaluation.
[0259] The experimental animals were randomly divided into groups, with 5 mice in each group. The immunization dose was 15 μg / mouse, and the same dose of booster immunization was given 2 weeks after vaccination. Twelve days after the second immunization, the cellular immune response and humoral immune response indicators were detected.
[0260] The mouse lymphocytes were separated according to the following method: the mice were killed by cervical dislocation and soaked in 75% ethanol; the mouse spleen was removed in a clean bench; 4mL-5mL mouse lymphocyte separation solution was placed in a 35mm culture dish (restored to room temperature and shaken before use); the separation solution containing spleen cells was immediately transferred to a 15mL centrifuge tube and centrifuged at room temperature in a horizontal rotor at 800g for 30 minutes. After centrifugation, the lymphocyte layer was aspirated, and 10mL RPMI 1640 culture medium was added, and the tube was inverted for washing. The cells were collected by centrifugation at room temperature. The experimental process can be found in Figure 3 .
[0261] 1. ELISA detection of RSV-F protein-specific IgG antibodies in mouse serum (humoral immunity)
[0262] The wild-type hRSV F protein (His Tag) (2 mg / mL) diluted to 2 μg / mL was added to the multi-well plate (100 μL per well) with washing solution and coated overnight. After washing, 2% BSA solution was added for blocking.
[0263] All serum samples to be tested were diluted with washing solution in a 10-fold gradient starting from 1:100 to 1:1,000,000. The negative control samples were kept consistent with the serum samples to be tested and were diluted by the same multiple. There were a total of 6 gradient samples.
[0264] Add the prepared serum sample solution to the enzyme-labeled multi-well plate, incubate and wash, add the diluted enzyme-labeled antibody solution, incubate and wash, perform color development, and measure the OD value at 450nm / 630nm on an enzyme reader.
[0265] The cutoff value was 2.1 times the arithmetic mean of the negative serum sample signal.
[0266] 2. Flow cytometry detection of TNFα+CD4+ and TNF-α+CD8+ T cells (cellular immunity)
[0267] Separated mouse lymphocytes were taken, stimulated with peptide library, and cultured in a 37°C, 5% CO2 incubator for 72 hours. BD GolgiPlμgTM (containing Brefeldin A) protein transport inhibitor (containing BSA) solution was used for stimulation overnight. The mouse lymphocyte suspension was centrifuged to retain the precipitate.
[0268] Resuspend the mouse lymphocyte pellet, add specific monoclonal fluorescent antibodies, such as CD4, CD8, etc., incubate and centrifuge to retain the mouse lymphocyte pellet.
[0269] Add fixation / permeabilization solution, incubate and centrifuge to obtain mouse lymphocyte pellet. Add buffer to mouse lymphocyte pellet, mix and centrifuge to obtain mouse lymphocyte pellet.
[0270] Resuspend the mouse lymphocyte precipitate with staining buffer, add cytokine fluorescent antibodies, such as IFN-γ, TNF-α, etc., incubate in the dark and centrifuge to retain the mouse lymphocyte precipitate. Then resuspend the mouse lymphocyte precipitate with staining buffer and detect it on flow cytometer.
[0271] The expression of TNF-α in CD3+ / CD4+ and CD3+ / CD8+ T lymphocytes was detected by flow cytometry.
[0272] 3. Flow cytometry detection of IFN-γ+CD4+ and IFN-γ+CD8+ T cells (cellular immunity)
[0273] Separated mouse lymphocytes were taken, stimulated with peptide library, and cultured in a 37°C, 5% CO2 incubator for 72 hours. BD GolgiPlμgTM (containing Brefeldin A) protein transport inhibitor (containing BSA) solution was used for stimulation overnight. The mouse lymphocyte suspension was centrifuged to retain the precipitate.
[0274] Resuspend the mouse lymphocyte pellet, add specific monoclonal fluorescent antibodies, such as CD4, CD8, etc., incubate and centrifuge to retain the mouse lymphocyte pellet.
[0275] Add fixation / permeabilization solution, incubate and centrifuge to obtain mouse lymphocyte pellet. Add buffer to mouse lymphocyte pellet, mix and centrifuge to obtain mouse lymphocyte pellet.
[0276] Resuspend the mouse lymphocyte precipitate with staining buffer, add cytokine fluorescent antibodies, such as IFN-γ, TNF-α, etc., incubate in the dark and centrifuge to retain the mouse lymphocyte precipitate. Then resuspend the mouse lymphocyte precipitate with staining buffer and detect it on flow cytometer.
[0277] The expression of IFN-γ in CD3+ / CD4+ and CD3+ / CD8+ T lymphocytes was detected by flow cytometry.
[0278] 4. ELISA detection of IFN-γ and IL2 in cell culture supernatant (cellular immunity)
[0279] Separated mouse lymphocytes were taken, stimulated with peptide library, and cultured in a 37°C, 5% CO2 incubator for 72 hours. The mouse lymphocyte suspension was centrifuged to obtain the supernatant.
[0280] Mouse IL-2 ELISA kit (purchased from Xinbosheng Biotechnology Co., Ltd.) and mouse IFN-γ ELISA kit (purchased from Xinbosheng Biotechnology Co., Ltd.) were used to detect the supernatant IFN-γ and IL2 contents.
[0281] 5. ELISA detection of IL4 and IL10 in cell culture supernatant (cellular immunity)
[0282] Separated mouse lymphocytes were taken, stimulated with peptide library, and cultured in a 37°C, 5% CO2 incubator for 72 hours. The mouse lymphocyte suspension was centrifuged to obtain the supernatant.
[0283] Mouse IL-4 ELISA kit (purchased from Xinbosheng Biotechnology Co., Ltd.) and mouse IL-10 ELISA kit (purchased from Xinbosheng Biotechnology Co., Ltd.) were used to detect the supernatant IL4 and IL10 contents.
[0284] 6. Neutralizing activity of serum
[0285] The neutralizing activity detection method of the serum of the immune combination group is as follows:
[0286] HEp-2 cells were digested, the cell density was adjusted, seeded into 96-well plates, and cultured overnight.
[0287] Each mouse serum dilution and virus dilution were added to the positive wells of the multi-well plate, and the virus dilution was added to the negative wells. Then, the diluted virus was added to the positive wells and negative wells of the multi-well plate, and the mixture was incubated for neutralization.
[0288] The neutralized products in the positive wells and negative wells of the multi-well plate were added to the multi-well plate containing the digested HEp-2 cells, respectively, and cultured; the neutralized products were aspirated, and DMEM+2% FBS culture medium was added to each well to continue the culture.
[0289] The supernatant of the cells was discarded, 4% paraformaldehyde was added to each well to fix the cells, PBS washing solution was used to wash, and the cells were blocked with a 1:1 mixture of 4% BSA and 0.2% triton. The blocking solution was discarded, and the F6-6-488 antibody dilution solution was added, incubated and washed; the multi-well plate was dried and read using a CTL device.
[0290] Example 5
[0291] The nucleotide sequences described in the following table are mRNA sequences. The mRNA sequences described in the following table are prepared into lipid nanoparticles containing RNA encoding respiratory syncytial virus antigens according to the method described in Example 1.
[0292] Table 3
[0293] Sample name Amino acid sequence ORF nucleotide sequence Wt Seq ID NO.24 Seq ID NO.25 F7-5 Seq ID NO.70 Seq ID NO.71 DS-Cav1 Seq ID NO.26 Seq ID NO.27 DS-Cav1+Tric Seq ID NO.32 Seq ID NO.33
[0294] The mRNA in the mRNA immune composition encoding respiratory syncytial virus antigen includes, in addition to the reading frame sequence in the above table, a 5' cap (m7Gppp (5')), a 5' UTR (as shown in Seq ID NO.16), a 3' UTR (as shown in Seq ID NO.19) and a 3' polyA tail of 100 adenine nucleotides; and the uracil of the mRNA is replaced with a 5' pseudouracil.
[0295] In addition to the above lipid nanoparticles containing RNA encoding respiratory syncytial virus antigens, an F protein (F-Protein) experimental group and a PBS blank control group were added into the experiment.
[0296] Sample Wt is an RNA lipid nanoparticle comprising an amino acid sequence encoding the wild-type RSV F protein; the amino acid sequence of the RSV F protein variant of sample F7-5 is based on the RSV F protein wild type, with S155C / S190F / V207L / S290C substitutions, and Fibritin Dominain is added to the C-terminus (the amino acid sequence is shown in Seq ID NO.7); the amino acid sequence of the RSV F protein variant encoded by sample DS-Cav1 is based on the RSV F protein wild type, with S155C / S190F / V207L / S290C substitutions; the amino acid sequence of the RSV F protein variant encoded by sample DS-Cav1+Tric is based on the RSV F protein wild type, with S155C / S190F / V207L / S290C substitutions, the TM sequence is deleted, and Fibritin Dominain is added to the C-terminus (the amino acid sequence is shown in Seq ID NO.7).
[0297] The vaccine immunogenicity of the prepared lipid nanoparticles encoding RNA for respiratory syncytial virus antigens was evaluated according to the method of Example 4.
[0298] 1. Flow cytometry detection of TNFα+CD4+ and TNF-α+CD8+ T cells
[0299] Results Figure 4 . The results showed that there was no significant difference in TNF-α+CD8+ between the mRNA immune composition group and the F-protein immune composition group (P>0.01). There was no significant difference in TNF-α+CD4+ between the mRNA immune composition group and the F-protein immune composition group (P>0.01). Compared with the PBS group, both the mRNA immune composition group and the F-protein immune composition group could significantly stimulate Th1 cell immune response (P<0.01).
[0300] 2. ELISA detection of IFN-γ and IL4 in cell culture supernatant
[0301] IFN-γ test results are shown in Figure 5 The results showed that there was no significant difference in IFN-γ between the mRNA immune composition group and the F-protein immune composition group (P>0.01). Compared with the PBS group, both the mRNA immune composition group and the F-protein immune composition group could significantly stimulate Th1 cell immune response.
[0302] IL4 test results are shown in Figure 5 The results showed that, except for the DS-Cav1 immune composition group, the IL-4 levels of the other mRNA immune composition groups were significantly higher than those of the F-protein immune composition group (P<0.01). Compared with the PBS group, both the mRNA immune composition group and the F-protein immune composition group could significantly stimulate Th2 cell immune response.
[0303] 3. Neutralizing activity of serum
[0304] 14 days after the second immunization, the RSV live virus tropism reduction experiment was performed to detect the RSV neutralizing antibody titer in the mouse serum. Figure 6 Compared with the RSV F protein wild-type mRNA immune composition group and other RSV F protein mutant mRNA immune composition groups, the RSV neutralizing antibody geometric mean titer of the F7-5 immune composition group was 10119.3, which was significantly higher than that of other mRNA immune composition groups, F-Protein immune composition groups and PBS control group (P<0.01).
[0305] In this embodiment, the RSV F protein mutant mRNA immune composition group based on the RSV F protein wild type with S155C / S190F / V207L / S290C substitutions, when retaining the TM sequence and adding the multimerization element (such as sample F7-5), has a significantly higher RSV neutralizing antibody titer in mouse serum than when only retaining the TM sequence (such as sample DS-Cav1) or only adding the multimerization element (such as sample DS-Cav1+Tric).
[0306] Example 6
[0307] According to the method described in Example 2, lipid nanoparticles containing RNA encoding respiratory syncytial virus antigens were prepared, namely samples Wt, F7, F7-3, F7-1, and F7-2.
[0308] The sequence of the RNA open reading frame in the lipid nanoparticles containing RNA encoding respiratory syncytial virus antigen described in sample Wt is shown in Seq ID NO.25, and the encoded respiratory syncytial virus antigen is the wild type of RSVF protein (the amino acid sequence is shown in Seq ID NO.24).
[0309] The sequence of the RNA open reading frame in the lipid nanoparticles containing RNA encoding the respiratory syncytial virus antigen described in sample F7 is shown in Seq ID NO.23, and the encoded respiratory syncytial virus antigen is a RSV F protein mutant (amino acid sequence as shown in Seq ID NO.22). The amino acid sequence of the RSV F protein variant encoded in sample F7 is based on the RSV F protein wild type, with S155C / S190F / V207L / S290C / D486C / D489C substitutions, the P27 sequence is replaced by the GS sequence shown in Seq ID NO.74, the TM sequence is deleted, and Fibritin Dominain (amino acid sequence as shown in Seq ID NO.7) is added to the C-terminus.
[0310] The sequence of the RNA open reading frame in the lipid nanoparticles containing RNA encoding a respiratory syncytial virus antigen described in sample F7-3 is shown in Seq ID NO.29, and the encoded respiratory syncytial virus antigen is a RSV F protein mutant (amino acid sequence as shown in Seq ID NO.28). The amino acid sequence of the RSV F protein variant encoded in sample F7-3 is based on the RSV F protein wild type, with S155C / S190F / V207L / S290C / D486C / D489C substitutions, the P27 sequence is replaced by the GS sequence shown in Seq ID NO.28, the TM sequence is deleted, and GCN4 Dominain (amino acid sequence as shown in Seq ID NO.12) is added to the C-terminus.
[0311] The sequence of the RNA open reading frame in the lipid nanoparticles containing RNA encoding a respiratory syncytial virus antigen described in sample F7-1 is shown in Seq ID NO.63, and the encoded respiratory syncytial virus antigen is a RSV F protein mutant (amino acid sequence as shown in Seq ID NO.62). The amino acid sequence of the RSV F protein variant encoded in sample F7-1 is based on the RSV F protein wild type, with S155C / S190F / V207L / S290C / D486C / D489C substitutions, the P27 sequence is replaced by the GS sequence shown in Seq ID NO.74, and Fibritin Dominain (amino acid sequence as shown in Seq ID NO.7) is added to the C-terminus.
[0312] The sequence of the RNA open reading frame in the lipid nanoparticles containing RNA encoding a respiratory syncytial virus antigen described in sample F7-2 is shown in Seq ID NO.65, and the encoded respiratory syncytial virus antigen is a RSV F protein mutant (amino acid sequence is shown in Seq ID NO.64). The amino acid sequence of the RSV F protein variant encoded in sample F7-2 is based on the RSV F protein wild type, with S155C / S190F / V207L / S290C / D486C / D489C substitutions, and the P27 sequence is replaced by the GS sequence shown in Seq ID NO.74.
[0313] The mRNA in the mRNA immune composition encoding respiratory syncytial virus antigen includes, in addition to the above-mentioned reading frame sequence, a 5' cap (m7Gppp (5')), a 5' UTR (as shown in Seq ID NO.16), a 3' UTR (as shown in Seq ID NO.19) and a 3' polyA tail of 100 adenine nucleotides; and the uracil of the mRNA is replaced by a 5' pseudouracil.
[0314] In addition to the above lipid nanoparticles containing RNA encoding respiratory syncytial virus antigens, F protein (F-Protein, purchased from Sino Biological, Beijing Yiqiao Shenzhou Science and Technology Co., Ltd.) was added to the experimental group and PBS blank control group.
[0315] The vaccine immunogenicity of the prepared lipid nanoparticles encoding RNA for respiratory syncytial virus antigens was evaluated according to the method of Example 4.
[0316] (1) ELISA detection of RSV-F protein-specific IgG in serum
[0317] 14 days after the second immunization, ELISA was used to detect RSV-F protein-specific IgG antibodies in mouse serum. The serum was diluted from 100 times to 10 million times, and OD450 was measured by indirect ELISA. The specific IgG antibody titer of mice in the RSV F protein mRNA immune composition group was statistically analyzed. The results showed that (see Figure 7 ), there was no significant difference in IgG antibody titer between the RSV F protein wild-type mRNA immune composition group (Wt) and the RSV F protein mutant mRNA immune composition group (F7, F7-3, F7-1 and F7-2) compared with the F-protein immune composition group.
[0318] (2) Flow cytometry detection of TNFα+CD4+ and TNF-α+CD8+ T cells
[0319] 14 days after immunization, the spleen lymphocytes of mice were isolated and the expression of TNF-α in CD3+ / CD4+ and CD3+ / CD8+ T lymphocytes was detected by flow cytometry. Figure 8 .
[0320] The results showed that the TNF-α+CD8+ in the F7-3 immune composition group and the F7-2 immune composition group was significantly higher than that in the F-protein immune composition group (P<0.01). There was no significant difference in TNF-α+CD4+ between the mRNA immune composition group and the F-protein immune composition group (P>0.01). The TNF-α+CD8+ / CD4+ in the RSV F protein wild-type mRNA immune composition group (Wt) and the RSV F protein mutant mRNA immune composition groups (F7, F7-3, F7-1 and F7-2) and the F-protein immune composition group were significantly higher than those in the PBS group (P<0.01).
[0321] The above results show that the RSVF protein wild-type mRNA immune composition group (Wt), the RSVF protein mutant mRNA immune composition group (F7, F7-3, F7-1 and F7-2) and the F-protein immune composition group can all significantly stimulate the Th1 cellular immune response of mice.
[0322] (3) ELISA detection of IFN-γ and IL-2 in the supernatant of spleen T lymphocyte culture medium
[0323] 14 days after immunization, the expression of IFN-γ and IL-2 in the lymphocyte supernatant was detected by ELISA. Fig. 9 .
[0324] The results showed that the IFN-γ in the F7-3, F7-1 and F7-2 immune composition groups was significantly higher than that in the F-protein immune composition group (P<0.01). The IL-2 in the F7-3 and F7-2 immune composition groups was significantly higher than that in the F-protein immune composition group (P<0.01). The IFN-γ and IL-2 in the RSV F protein wild-type mRNA immune composition group (Wt), RSV F protein mutant mRNA immune composition groups (F7, F7-3, F7-1 and F7-2) and F-protein immune composition groups were significantly higher than those in the PBS group (P<0.01).
[0325] (4) ELISA detection of IL-4 and IL-10 in the supernatant of spleen T lymphocyte culture medium
[0326] 14 days after immunization, the expression of IL-4 and IL-10 in lymphocyte supernatant was detected by ELISA. Fig.10. The results showed that the IL-4 levels of the F7-3 immune composition group and the F7-2 immune composition group were significantly higher than those of the F-protein immune composition group (P<0.01). The IL-10 levels of the F7-1 immune composition group were significantly higher than those of the F-protein immune composition group (P<0.01). The IL-4 and IL-10 levels of the RSV F protein wild-type mRNA immune composition group (Wt), the RSV F protein mutant mRNA immune composition groups (F7, F7-3, F7-1 and F7-2) and the F-protein immune composition group were significantly higher than those of the PBS group (P<0.01).
[0327] The above results show that the RSVF protein wild-type mRNA immune composition group (Wt), the RSVF protein mutant mRNA immune composition group (F7, F7-3, F7-1 and F7-2) and the F-protein immune composition group can all significantly stimulate the Th2 cellular immune response of mice.
[0328] (5) RSV neutralizing antibody titer in serum
[0329] 14 days after the second immunization, the RSV live virus tropism reduction experiment was used to detect the RSV neutralizing antibody titer in the mouse serum. Fig.11 As shown, compared with the RSV F protein wild-type mRNA immune composition group (Wt), the RSV F protein mutant mRNA immune composition group (F7-3, F7 and F7-2) and the F-protein immune composition group, the RSV neutralizing antibody geometric mean titer of the F7-1 immune composition group was 36162, which was significantly higher than that of other mRNA immune composition groups (P<0.01).
[0330] In this embodiment, the RSV F protein mutant mRNA immune composition group based on the RSV F protein wild type, with S155C / S190F / V207L / S290C substitutions, D486C / D489C substitutions, and the P27 sequence replaced by the GS sequence shown in Seq ID NO.74, when the TM sequence is retained and the multimerization element is added (such as sample F7-1), the RSV neutralizing antibody titer in the mouse serum is significantly higher than that of only retaining the TM sequence (such as sample F7-2) or only adding the multimerization element (such as sample F7).
[0331] Example 7
[0332] According to the method described in Example 2, lipid nanoparticles containing RNA encoding respiratory syncytial virus antigens were prepared, namely samples Wt, F7-1, DS-Cav1 and mVRC-1 (v2).
[0333] The sequence of the RNA open reading frame in the lipid nanoparticles containing RNA encoding respiratory syncytial virus antigen described in sample Wt is shown in Seq ID NO.25, and the encoded respiratory syncytial virus antigen is the wild type of RSVF protein (the amino acid sequence is shown in Seq ID NO.24).
[0334] The sequence of the RNA open reading frame in the lipid nanoparticles containing RNA encoding a respiratory syncytial virus antigen described in sample F7-1 is shown in Seq ID NO.63, and the encoded respiratory syncytial virus antigen is a RSV F protein mutant (amino acid sequence as shown in Seq ID NO.62). The amino acid sequence of the RSV F protein variant encoded in sample F7-1 is based on the RSV F protein wild type, with S155C / S190F / V207L / S290C / D486C / D489C substitutions, the P27 sequence is replaced by the GS sequence shown in Seq ID NO.74, and Fibritin Dominain (amino acid sequence as shown in Seq ID NO.7) is added to the C-terminus.
[0335] The sequence of the RNA open reading frame in the lipid nanoparticle containing RNA encoding the respiratory syncytial virus antigen described in sample DS-Cav1 is shown in Seq ID NO.27, and the encoded respiratory syncytial virus antigen is a RSV F protein mutant (amino acid sequence is shown in Seq ID NO.26). The amino acid sequence of the RSV F protein variant encoded by sample DS-Cav1 is based on the RSV F protein wild type, and S155C / S190F / V207L / S290C substitution occurs.
[0336] The sequence of the RNA open reading frame in the lipid nanoparticles containing RNA encoding respiratory syncytial virus antigen described in sample mVRC-1 (v2) is shown in Seq ID NO.31, and the encoded respiratory syncytial virus antigen is an RSVF protein mutant (amino acid sequence is shown in Seq ID NO.30).
[0337] The mRNA in the RNA immune composition encoding respiratory syncytial virus antigen includes, in addition to the above-mentioned reading frame sequence, a 5' cap (m7Gppp (5')), a 5' UTR (as shown in Seq ID NO.16), a 3' UTR (as shown in Seq ID NO.19) and a 3' polyA tail of 100 adenine nucleotides; and the uracil of the mRNA is replaced by a 5' pseudouracil.
[0338] In addition to the above lipid nanoparticles containing RNA encoding respiratory syncytial virus antigens, an F protein (F-Protein) experimental group and a PBS blank control group were added into the experiment.
[0339] The vaccine immunogenicity of the prepared lipid nanoparticles encoding RNA for respiratory syncytial virus antigens was evaluated according to the method of Example 4.
[0340] (1) Flow cytometry detection of TNFα+CD4+ and TNF-α+CD8+ T cells
[0341] 14 days after immunization, the spleen lymphocytes of mice were isolated and the expression of TNF-α in CD3+ / CD4+ and CD3+ / CD8+ T lymphocytes was detected by flow cytometry. Fig.12 .
[0342] The results showed that there was no significant difference in TNF-α+CD8+ between the mRNA immune composition group and the F-protein immune composition group (P>0.01). There was no significant difference in TNF-α+CD4+ between the mRNA immune composition group and the F-protein immune composition group (P>0.01). Compared with the PBS group, both the mRNA immune composition group and the F-protein immune composition group could significantly stimulate Th1 cell immune response.
[0343] (2) Flow cytometry detection of IFN-γ+CD4+ and IFN-γ+CD8+ T cells
[0344] 14 days after immunization, the spleen lymphocytes of mice were isolated and the expression of IFN-γ+ in CD3+ / CD4+ and CD3+ / CD8+ T lymphocytes was detected by flow cytometry. Fig.13 .
[0345] The results showed that the IFN-γ+CD8+ in the mRNA immune composition group was significantly higher than that in the F-protein immune composition group (P<0.01). Except for the mVRC-1(v2) immune composition group, the IFN-γ+CD4+ in the other mRNA immune composition groups was significantly higher than that in the F-protein immune composition group (P<0.01). Compared with the PBS group, both the mRNA immune composition group and the F-protein immune composition group could significantly stimulate the Th1 cell immune response.
[0346] (3) ELISA detection of IFN-γ and IL-2 in the supernatant of spleen T lymphocyte culture medium
[0347] 14 days after immunization, the expression of IFN-γ and IL-2 in the lymphocyte supernatant was detected by ELISA. Fig.14. The results showed that there was no significant difference in IFN-γ between the mRNA immune composition group and the F-protein immune composition group (P>0.01). Except for the Wt immune composition group, the IL-2 of the other mRNA immune composition groups was significantly higher than that of the F-protein immune composition group (P<0.01). Compared with the PBS group, both the mRNA immune composition group and the F-protein immune composition group could significantly stimulate Th1 cell immune response.
[0348] (4) ELISA detection of IL-4 and IL-10 in the supernatant of spleen T lymphocyte culture medium
[0349] 14 days after immunization, the expression of IL-4 and IL-10 in lymphocyte supernatant was detected by ELISA. Fig.15 . The results showed that, except for the DS-Cav1 immune composition group, the IL-4 levels of the other mRNA immune composition groups were significantly higher than those of the F-protein immune composition group (P<0.01). Except for the DS-Cav1 immune composition group, the IL-10 levels of the other mRNA immune composition groups were significantly higher than those of the F-protein immune composition group (P<0.01). Compared with the PBS group, both the mRNA immune composition group and the F-protein immune composition group could significantly stimulate Th2 cell immune response.
[0350] (5) RSV neutralizing antibody titer in serum
[0351] 14 days after the second immunization, the RSV live virus tropism reduction experiment was used to detect the RSV neutralizing antibody titer in the mouse serum. Fig.16 As shown, compared with other mRNA immune composition groups, the RSV neutralizing antibody geometric mean titer of the F7-1 immune composition group was 20821, which was significantly higher than that of other mRNA immune composition groups (P<0.01).
[0352] Example 8
[0353] According to the method described in Example 2, lipid nanoparticles containing RNA encoding respiratory syncytial virus antigens were prepared, namely samples Wt, F7-1, F7-2, F7-3, F7-4, F7-5 and F7-6.
[0354] The sequence of the RNA open reading frame in the lipid nanoparticles containing RNA encoding respiratory syncytial virus antigen described in sample Wt is shown in Seq ID NO.25, and the encoded respiratory syncytial virus antigen is the wild type of RSVF protein (the amino acid sequence is shown in Seq ID NO.24).
[0355] The sequence of the RNA open reading frame in the lipid nanoparticles containing RNA encoding a respiratory syncytial virus antigen described in sample F7-1 is shown in Seq ID NO.63, and the encoded respiratory syncytial virus antigen is a RSV F protein mutant (amino acid sequence as shown in Seq ID NO.62). The amino acid sequence of the RSV F protein variant encoded in sample F7-1 is based on the RSV F protein wild type, with S155C / S190F / V207L / S290C / D486C / D489C substitutions, the P27 sequence is replaced by the GS sequence shown in Seq ID NO.74, and Fibritin Dominain (amino acid sequence as shown in Seq ID NO.7) is added to the C-terminus.
[0356] The sequence of the RNA open reading frame in the lipid nanoparticles containing RNA encoding a respiratory syncytial virus antigen described in sample F7-2 is shown in Seq ID NO.65, and the encoded respiratory syncytial virus antigen is a RSV F protein mutant (amino acid sequence is shown in Seq ID NO.64). The amino acid sequence of the RSV F protein variant encoded in sample F7-2 is based on the RSV F protein wild type, with S155C / S190F / V207L / S290C / D486C / D489C substitutions, and the P27 sequence is replaced by the GS sequence shown in Seq ID NO.74.
[0357] The sequence of the RNA open reading frame in the lipid nanoparticles containing RNA encoding a respiratory syncytial virus antigen described in sample F7-3 is shown in Seq ID NO.67, and the encoded respiratory syncytial virus antigen is a RSV F protein mutant (amino acid sequence as shown in Seq ID NO.66). The amino acid sequence of the RSV F protein variant encoded in sample F7-3 is based on the RSV F protein wild type, with S155C / S190F / V207L / S290C / D486C / D489C substitutions, the P27 sequence is replaced by the GS sequence shown in Seq ID NO.74, and GCN4 Dominain (amino acid sequence as shown in Seq ID NO.12) is added to the C-terminus.
[0358] The sequence of the RNA open reading frame in the lipid nanoparticles containing RNA encoding a respiratory syncytial virus antigen described in sample F7-4 is shown in Seq ID NO.69, and the encoded respiratory syncytial virus antigen is a RSV F protein mutant (amino acid sequence as shown in Seq ID NO.68). The amino acid sequence of the RSV F protein variant encoded in sample F7-4 is based on the RSV F protein wild type, with S155C / S190F / V207L / S290C substitutions, the P27 sequence is replaced by the GS sequence shown in Seq ID NO.74, and Fibritin Dominain (amino acid sequence as shown in Seq ID NO.7) is added to the C-terminus.
[0359] The sequence of the RNA open reading frame in the lipid nanoparticles containing RNA encoding a respiratory syncytial virus antigen described in sample F7-5 is shown in Seq ID NO.71, and the encoded respiratory syncytial virus antigen is a RSV F protein mutant (amino acid sequence is shown in Seq ID NO.70). The amino acid sequence of the RSV F protein variant encoded by sample F7-5 is based on the RSV F protein wild type, with S155C / S190F / V207L / S290C substitutions, and Fibritin Dominain is added to the C-terminus (amino acid sequence is shown in Seq ID NO.7).
[0360] The sequence of the RNA open reading frame in the lipid nanoparticles containing RNA encoding a respiratory syncytial virus antigen described in sample F7-6 is shown in Seq ID NO.73, and the encoded respiratory syncytial virus antigen is a RSV F protein mutant (amino acid sequence is shown in Seq ID NO.72). The amino acid sequence of the RSV F protein variant encoded in sample F7-6 is based on the RSV F protein wild type, with S155C / S190F / V207L / S290C / D486C / D489C substitutions, and Fibritin Dominain is added to the C-terminus (amino acid sequence is shown in Seq ID NO.7).
[0361] The mRNA in the RNA immune composition encoding respiratory syncytial virus antigen includes, in addition to the above-mentioned reading frame sequence, a 5' cap (m7Gppp (5')), a 5' UTR (as shown in Seq ID NO.16), a 3' UTR (as shown in Seq ID NO.19) and a 3' polyA tail of 100 adenine nucleotides; and the uracil of the mRNA is replaced by a 5' pseudouracil.
[0362] In addition to the above lipid nanoparticles containing RNA encoding respiratory syncytial virus antigens, a PBS blank control group was added to the experiment.
[0363] The vaccine immunogenicity of the prepared lipid nanoparticles encoding RNA for respiratory syncytial virus antigens was evaluated according to the method of Example 4.
[0364] (1) Flow cytometry detection of TNFα+CD4+ and TNF-α+CD8+ T cells
[0365] 14 days after immunization, the spleen lymphocytes of mice were isolated and the expression of TNF-α in CD3+ / CD4+ and CD3+ / CD8+ T lymphocytes was detected by flow cytometry. Fig.17 .
[0366] The results showed that the TNF-α+CD8+ in the F7-1 immune composition group was not significantly different from that in the other mRNA immune composition groups (P>0.01). No significant increase in TNF-α+CD4+ was detected in the mRNA immune composition group (P>0.01). Compared with the PBS group, the mRNA immune composition group could significantly stimulate the Th1 cell immune response.
[0367] (2) Flow cytometry detection of IFN-γ+CD4+ and IFN-γ+CD8+ T cells
[0368] 14 days after immunization, the spleen lymphocytes of mice were isolated and the expression of IFN-γ+ in CD3+ / CD4+ and CD3+ / CD8+ T lymphocytes was detected by flow cytometry. Fig.18 .
[0369] The results showed that, except for the F7-2 immune composition group, the IFN-γ+CD8+ in the F7-1 immune composition group was not significantly different from that in the other mRNA immune composition groups. No significant increase in IFN-γ+CD4+ was detected in the mRNA immune composition group (P>0.01). Compared with the PBS group, the mRNA immune composition groups could significantly stimulate the Th1 cell immune response.
[0370] (3) ELISA detection of IFN-γ and IL-2 in the supernatant of spleen T lymphocyte culture medium
[0371] 14 days after immunization, the expression of IFN-γ and IL-2 in the lymphocyte supernatant was detected by ELISA. Fig.19 The results showed that, except for the F7-4 and F7-6 immune composition groups, there was no significant difference in IFN-γ in the F7-1 immune composition group compared with other mRNA immune composition groups. IL-2 detected in the F7-1 immune composition group was significantly higher than that in other mRNA immune composition groups (P<0.01). Compared with the PBS group, the mRNA immune composition groups could significantly stimulate Th1 cell immune response.
[0372] (4) ELISA detection of IL-4 and IL-10 in the supernatant of spleen T lymphocyte culture medium
[0373] 14 days after immunization, the expression of IL-4 and IL-10 in lymphocyte supernatant was detected by ELISA. Fig. 20 . The results showed that, except for the Wt and F7-3 immune composition groups, the IL-4 in the F7-1 immune composition group was not significantly different from that in the other mRNA immune composition groups. Except for the Wt, F7-2 and F7-3 immune composition groups, the IL-10 in the F7-1 immune composition group was significantly increased compared with that in the other mRNA immune composition groups. Compared with the PBS group, the mRNA immune composition groups could significantly stimulate the Th2 cell immune response.
[0374] (5) RSV neutralizing antibody titer in serum
[0375] 14 days after the second immunization, the RSV live virus tropism reduction experiment was used to detect the RSV neutralizing antibody titer in the mouse serum. Fig.21 As shown in the figure, compared with the mRNA immune composition group, the RSV neutralizing antibody geometric mean titer of the F7-1 immune composition group was 20730, which was significantly higher than that of other mRNA immune composition groups and the F-Protein immune composition group (P<0.01); the RSV neutralizing antibody geometric mean titer of the F7-3 immune composition group was 16026, and the RSV neutralizing antibody geometric mean titer of the F7-5 immune composition group was 10871, which were significantly higher than those of the Wt, F7-2, F7-4, F7-6 immune composition groups and the F-Protein immune composition group (P<0.01).
[0376] Example 9
[0377] According to the method described in Example 2, lipid nanoparticles containing RNA encoding respiratory syncytial virus antigens were prepared, namely samples Wt, F7-1, F7-a and F7-b.
[0378] The sequence of the RNA open reading frame in the lipid nanoparticles containing RNA encoding respiratory syncytial virus antigen described in sample Wt is shown in Seq ID NO.25, and the encoded respiratory syncytial virus antigen is the wild type of RSVF protein (the amino acid sequence is shown in Seq ID NO.24).
[0379] The sequence of the RNA open reading frame in the lipid nanoparticles containing RNA encoding respiratory syncytial virus antigen described in sample F7-1 is shown in Seq ID NO.63, and the encoded respiratory syncytial virus antigen is an RSV F protein mutant (the amino acid sequence is shown in Seq ID NO.62).
[0380] The sequence of the RNA open reading frame in the lipid nanoparticles containing RNA encoding respiratory syncytial virus antigen described in sample F7-a is shown in Seq ID NO.77, and the encoded respiratory syncytial virus antigen is an RSV F protein mutant (the amino acid sequence is shown in Seq ID NO.76).
[0381] The sequence of the RNA open reading frame in the lipid nanoparticles containing RNA encoding respiratory syncytial virus antigen described in sample F7-b is shown in Seq ID NO.79, and the encoded respiratory syncytial virus antigen is an RSV F protein mutant (the amino acid sequence is shown in Seq ID NO.78).
[0382] In addition to the above-mentioned nucleotide ORF sequence, the sequences of these RNA vaccines also include a 5' cap (m7Gppp (5')), a 5'UTR (as shown in Seq ID NO.16), a 3'UTR (as shown in Seq ID NO.19) and a 3'polyA tail of 100 adenine nucleotides; and the uracil of the mRNA is replaced with a 5'pseudouracil.
[0383] In addition to the above lipid nanoparticles containing RNA encoding respiratory syncytial virus antigens, a PBS blank control group was added to the experiment.
[0384] According to the method of Example 4, the RSV neutralizing antibody titer in serum was evaluated for the prepared lipid nanoparticles encoding RNA for respiratory syncytial virus antigens.
[0385] 14 days after the second immunization, the RSV live virus tropism reduction experiment was used to detect the RSV neutralizing antibody titer in the mouse serum. Fig. 22 As shown, compared with the Wt immune composition group, the RSV neutralizing antibody geometric mean titers of the F7-1 immune composition group, the F7-a immune composition group and the F7-b immune composition group were all over 18,000, which were significantly higher than those of the Wt immune composition group (P<0.01).
[0386] Example 10
[0387] The nucleotide sequences described in the table below are mRNA sequences. The mRNAs shown in the table below were transfected into cells, and the expression of RSV F full-length protein in the cells was detected. The results are shown in the table below.
[0388] The detailed method is as follows: HEK293 cells were lysed 24 hours after transfection of each mRNA, and the target protein was specifically detected by SDS-PAGE immunoblotting according to the loading amount of 10 μg total protein. In this embodiment, anti-RSVF protein antibody was used as the primary antibody and goat anti-mouse-HRP antibody was used as the secondary antibody for incubation, and then color was developed. When analyzing the results of protein expression detection, internal reference β-actin was used for standardization and quantification, and cells that were not transfected with mRNA were set as negative controls to compare the differences in protein expression after different mRNA transfection cells. The test results show that the expression of the full length of RSVF protein can be detected. The expression of each sequence is measured in relative OD values, as shown in the following table; wherein the relative OD value is calculated as follows: sample OD value / OD value of sample 1.
[0389] Table 4
[0390] Serial number ORF nucleotide sequence 3'UTR 5'UTR Relative expression 1 Seq ID NO.63 Seq ID NO.21 Seq ID NO.18 1 2 Seq ID NO.63 Seq ID NO.20 Seq ID NO.18 1.1 3 Seq ID NO.63 Seq ID NO.19 Seq ID NO.18 1.2 4 Seq ID NO.63 Seq ID NO.21 Seq ID NO.17 0.9 5 Seq ID NO.63 Seq ID NO.20 Seq ID NO.17 1.2 6 Seq ID NO.63 Seq ID NO.19 Seq ID NO.17 1.1 7 Seq ID NO.63 Seq ID NO.21 Seq ID NO.16 1.1 8 Seq ID NO.63 Seq ID NO.20 Seq ID NO.16 1.2 9 Seq ID NO.63 Seq ID NO.19 Seq ID NO.16 1.4
[0391] Embodiment 11
[0392] The RNA sequences numbered 1 to 9 in Table 4 in Example 10 were prepared into lipid nanoparticles containing RNA encoding respiratory syncytial virus antigens according to the method described in Example 2, which were samples 01 to 09 respectively.
[0393] In addition to the above-mentioned nucleotide sequences, the sequences of these RNA vaccines also include a 5' cap (m7Gppp(5')) and a 3' polyA tail of 100 adenine nucleotides; and the uracil of the mRNA is replaced with a 5' pseudouracil.
[0394] In addition to the above lipid nanoparticles containing RNA encoding respiratory syncytial virus antigen, a PBS blank control group was added into the experiment, and the sample Wt prepared according to Example 9 was expected.
[0395] According to the method of Example 4, the RSV neutralizing antibody titer in serum was evaluated for the prepared lipid nanoparticles encoding RNA for respiratory syncytial virus antigens.
[0396] 14 days after the second immunization, the RSV live virus tropism reduction experiment was used to detect the RSV neutralizing antibody titer in the mouse serum. Fig.23 As shown, compared with the Wt immune composition group, the geometric mean titers of RSV neutralizing antibodies in samples 01 to 09 were all over 10,000, significantly higher than that in the Wt immune composition group (P<0.01); and the geometric mean titer of RSV neutralizing antibodies in sample 09 was slightly higher than that in other samples 01 to 08.
[0397] Example 12
[0398] According to the method described in Example 2, lipid nanoparticles containing RNA encoding respiratory syncytial virus antigens were prepared, which were samples Wt, F124 to F138 respectively.
[0399] The sequence of the RNA open reading frame in the lipid nanoparticles containing RNA encoding respiratory syncytial virus antigen described in sample Wt is shown in Seq ID NO.25, and the encoded respiratory syncytial virus antigen is the wild type of RSVF protein (the amino acid sequence is shown in Seq ID NO.24).
[0400] The sequences of the RNA open reading frames in the lipid nanoparticles containing RNA encoding respiratory syncytial virus antigens described in samples 124 to 128 are shown in Seq ID NO.63 and Seq ID NOs.84 to 87, and the encoded respiratory syncytial virus antigen is an RSVF protein mutant (amino acid sequence is shown in Seq ID NO.62).
[0401] The sequences of the RNA open reading frames in the lipid nanoparticles containing RNA encoding respiratory syncytial virus antigens described in samples 129 to 133 are shown in Seq ID NO.67 and Seq ID NOs.88 to 91, and the encoded respiratory syncytial virus antigen is an RSVF protein mutant (amino acid sequence is shown in Seq ID NO.66).
[0402] The sequences of the RNA open reading frames in the lipid nanoparticles containing RNA encoding respiratory syncytial virus antigens described in samples 134 to 138 are shown in Seq ID NO.71 and Seq ID NOs.92 to 95, and the encoded respiratory syncytial virus antigen is an RSVF protein mutant (amino acid sequence is shown in Seq ID NO.70).
[0403] The sequences of the RNA open reading frames in the lipid nanoparticles containing RNA encoding respiratory syncytial virus antigens described in samples 139 to 143 are shown in Seq ID NO.77 and Seq ID NOs.96 to 99, and the encoded respiratory syncytial virus antigen is an RSVF protein mutant (amino acid sequence is shown in Seq ID NO.76).
[0404] The sequences of the RNA open reading frames in the lipid nanoparticles containing RNA encoding respiratory syncytial virus antigens described in samples 144 to 148 are shown in Seq ID NO.79 and Seq ID NOs.100 to 103, and the encoded respiratory syncytial virus antigen is an RSVF protein mutant (amino acid sequence is shown in Seq ID NO.78).
[0405] The sequence of the RNA open reading frame in the lipid nanoparticle containing RNA encoding the respiratory syncytial virus antigen is shown in Seq ID NO.103, and the encoded respiratory syncytial virus antigen is a RSV F protein mutant (the amino acid sequence is shown in Seq ID NO.78).
[0406] In addition to the above-mentioned nucleotide ORF sequence, the sequences of these RNA vaccines also include a 5' cap (m7Gppp (5')), a 5'UTR (as shown in Seq ID NO.16), a 3'UTR (as shown in Seq ID NO.19) and a 3'polyA tail of 100 adenine nucleotides; and the uracil of the mRNA is replaced with a 5'pseudouracil.
[0407] In addition to the above lipid nanoparticles containing RNA encoding respiratory syncytial virus antigens, a PBS blank control group was added to the experiment.
[0408] According to the method of Example 4, the RSV neutralizing antibody titer in serum was evaluated for the prepared lipid nanoparticles encoding RNA for respiratory syncytial virus antigens.
[0409] 14 days after the second immunization, the RSV live virus tropism reduction experiment was used to detect the RSV neutralizing antibody titer in the mouse serum. Figures 24-26 As shown, compared with the Wt immune composition group, the RSV neutralizing antibody geometric mean titers of the F124~F148 immune composition groups were all over 10,000, which were significantly higher than those of the Wt immune composition group (P<0.01).
[0410] The RSV neutralizing antibody titers of samples 124-128 and samples 140-148 whose respiratory syncytial virus antigens edited with amino acid sequences as shown in Seq ID NO.62, Seq ID NO.76 and Seq ID NO.78 are RSV F protein mutants are higher than those of other samples.
[0411] Embodiment 13
[0412] BALB / c mice (female, 5 weeks old, with an average body weight of about 19 g, purchased from Zhuhai Baishitong Biotechnology Co., Ltd.) were selected for vaccine immunogenicity evaluation. The experimental animals were randomly divided into 5 groups, with 6 mice in each group. The dosing schedules were as follows: (1) Vehicle group: intramuscular injection of 50 μg / mouse PBS buffer containing empty lipid nanoparticles; (2) F protein group: intramuscular injection of 50 μg / mouse PBS buffer containing 0.05 μg pre-fusion hRSV F protein; (3) F7-1 (5 μg) group: intramuscular injection of 25 μg / mouse PBS buffer containing 5 μg of lipid nanoparticles containing RNA encoding respiratory syncytial virus antigen, wherein the sequence of the RNA open reading frame is shown in Seq ID NO.63; (4) F7-1 (15 μg) group: intramuscular injection of 75 μg / mouse PBS buffer containing 15 μg of lipid nanoparticles containing RNA encoding respiratory syncytial virus antigen, wherein the sequence of the RNA open reading frame is shown in Seq ID NO.63; (5) Health group: no drug administration. The same dose of booster immunization was given on the 21st day after vaccination, and serum samples were collected after the 35th day after vaccination. On the 40th day after vaccination: the animals were killed and lung tissues were collected. On the 35th day after vaccination, mice in groups 1 to 4 were inoculated with RSV / A2 virus by nasal drops. The weight and weight changes of mice, as well as RSV-F protein-specific IgG antibodies, serum neutralizing activity, lung tissue virus titer detection of mice after RSV infection, and lung tissue pathology detection of mice after RSV infection were monitored during the experiment. The method for detecting the neutralizing activity of RSV-F protein-specific IgG antibodies and serum is shown in Example 4 of the present invention. HE staining was used to evaluate lung tissue lesions, perivascular, peribronchial, alveolar, and interstitial lung inflammation. Plaque assay was used to detect lung tissue virus titer.
[0413] Lipid nanoparticles containing RNA encoding respiratory syncytial virus antigens were prepared according to the method described in Example 2, which is sample F7-1. In addition to the above-mentioned nucleotide ORF sequence, the sequences of these RNA vaccines also include a 5' cap (m7Gppp (5')), a 5' UTR (as shown in Seq ID NO.16), a 3' UTR (as shown in Seq ID NO.19) and a 3' poly A tail of 100 adenine nucleotides; and the uracil of the mRNA is replaced with a 5' pseudouracil.
[0414] (1) Mouse body weight and body weight changes
[0415] The weight and weight changes of mice during the experiment are shown in Fig. 27 and Fig.28 As shown. On days 2 to 5 after the first vaccination, the body weight of the F7-1 (5 μg) and F7-1 (15 μg) immunization groups decreased significantly ( Fig. 27), the body weight of the F7-1 (5 μg) immunization group decreased by about 5% on the second day after the first vaccination, and the body weight of the F7-1 (15 μg) immunization group decreased by about 10% on the second day after the first vaccination ( Fig.28 On the first day after the second vaccination (22 days after the first vaccination), the body weight of the F7-1 (5 μg) and F7-1 (15 μg) immunization groups decreased significantly ( Fig. 27 ), the body weight of the F7-1 (5 μg) immunization group decreased by about 5% on the second day after the second vaccination, and the body weight of the F7-1 (15 μg) immunization group decreased by about 10% on the second day after the second vaccination ( Fig.28 ). Compared with the body weight before intranasal inoculation of RSV / A2 virus, the body weight of the Vehile immunization group decreased by about 3%, the body weight of the F protein immunization group decreased by about 5%, the body weight of the F7-1 (5 μg) immunization group decreased by about 4%, and the body weight of the F7-1 (15 μg) immunization group increased by 1% on the 5th day after the challenge.
[0416] (2) ELISA detection of RSV-F protein-specific IgG in serum
[0417] On the 35th day after the first vaccination, RSV-F protein-specific IgG antibodies in mouse serum were detected by ELISA. The serum was diluted from 100 times to 8 million times, and OD450 was measured by indirect ELISA.
[0418] The sample OD450 was ≥ 2 times the average OD450 of the minimum dilution factor (1:100) of the negative control group, and was judged as positive (Bao-ZhongWang, et al..PLoS ONE.2010; Teena Mohan, et al..J Control Release.2016). The final dilution titer was reached when the serum sample of the F7-1 (15μg) immune group was diluted to 8 million times.
[0419] The statistical results of the specific IgG antibody titer of RSV-F protein in serum are shown in Fig.29 The results showed that the IgG titer GMT value of the F7-1 (15μg) immunization group was the highest. The IgG antibody titer of the F7-1 (5μg) and F7-1 (15μg) immunization groups was significantly higher than that of the F protein immunization group.
[0420] (3) RSV neutralizing antibody titer in serum
[0421] 35 days after the first vaccination, RSV-A / B strain virus plaque reduction test was used to detect RSV neutralizing antibody titers in mouse serum. Fig.30As shown in the left figure, for RSV-A2 strain, the neutralizing antibody titers of the F7-1 (5 μg) (GMT = 20030) and F7-1 (15 μg) (GMT = 27335) immunization groups were significantly higher than those of the Fprotein (GMT = 54) immunization group (P < 0.05), and there was no significant difference between the F7-1 (5 μg) immunization group and the F7-1 (15 μg) immunization group, indicating that there was no significant difference between the high and low dose groups of the F7-1 vaccine; Fig.30 As shown in the right figure, for the RSV-18537 strain, the neutralizing antibody titer of the F7-1 (5μg) (GMT=4177) and F7-1 (15μg) (GMT=9392) immunization groups was significantly higher than that of the Fprotein (GMT=37) immunization group (P<0.05), and there was no significant difference in the neutralizing antibody titer between the F7-1 (5μg) immunization group and the F7-1 (15μg) immunization group (P>0.05), indicating that there was no significant difference between the high and low dose groups of F7-1.
[0422] (4) Virus titer in lung tissue of mice after RSV infection
[0423] On the fifth day after RSV infection, the RSV virus titer in the right lung tissue homogenate of mice after intranasal inoculation of RSV / A2 virus was determined by plaque reduction neutralization test (see Fig.31 ). The virus titer in lung tissue of Vehicle immunization group was significantly higher than that of F protein, F7-1 (5μg), F7-1 (15μg) and Health groups. Among them, F7-1 (5μg), F7-1 (15μg) and Health groups were all at the lower limit of quantitation (LLOQ). The results showed that F protein (RSV inactivated vaccine), F7-1 (5μg) and F7-1 (15μg) mRNA vaccines can significantly reduce the virus titer in lung tissue of immunized mice.
[0424] (5) Lung histopathology of mice after RSV infection
[0425] On the 5th day after RSV infection, HE staining was used to evaluate lung tissue lesions (perivascular, peribronchial, alveolar, and interstitial lung inflammation). Fig.32The perivascular, peribronchial, alveolar and interstitial inflammation scores of the F protein immunization group were significantly higher than those of the Vehicle immunization group. The Vehicle, 007-5μg and 007-15μg immunization groups all showed mild pathological reactions after RSV infection. In summary, these results indicate that the F7-1 (5μg) and F7-1 (15μg) immunization groups can induce high titers of IgG-specific antibodies and neutralizing antibodies, protecting animals from RSV infection without causing vaccine-enhanced respiratory disease (VERD).
[0426] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present disclosure, rather than to limit them. Although the present disclosure has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or replace some or all of the technical features therein by equivalents. However, these modifications or replacements do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present disclosure.
Claims
1. An immune composition comprising or encoding a human respiratory syncytial virus antigen, characterized in that: The immune composition is selected from a nucleic acid immune composition, a polypeptide immune composition or a virus immune composition; Preferably, the antigen is a pre-fusion hRSV F protein, and the amino acid sequence of the pre-fusion hRSV F protein includes a TM sequence and a multimerization element; preferably, the amino acid sequence of the multimerization element is as shown in Seq ID NO.1-12, Seq ID NO.14-15; preferably, the amino acid sequence of the multimerization element is as shown in one of Seq ID NO.7 and Seq ID NO.
12.
2. The immune composition according to claim 1, characterized in that The P27 sequence of the hRSV F protein before fusion is replaced with a GS sequence; preferably, the GS sequence comprises (GnS)m, (GGGGS)o, GGSGGGGSGG, GGSGGGGG, GSGSGSGS, (Gly)p, (EAAAK)q, Seq ID NO.48-61, Seq ID NO.74 (wherein n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15 or 20; m is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15 or 20; o is an integer from 1 to 5; p is an integer from 1 to 40; q is an integer from 1 to 5); preferably, the amino acid sequence of the GS sequence is as shown in Seq ID NO.74; Preferably, the pre-fusion hRSV F protein includes at least one of S46G substitution, N67I substitution, E92D substitution, P102A substitution, A149C substitution, S155C substitution, S190F substitution, V207L substitution, S290C substitution, L373R substitution, S215P substitution, I379V substitution, M447V substitution, Y458C substitution, K465Q substitution, D486C substitution, and D489C substitution.
3. The immune composition according to claim 1 or 2, characterized in that The amino acid sequence of the hRSV F protein before fusion includes at least one of S155C substitution, S190F substitution, V207L substitution, S290C substitution, D486C substitution, and D489C substitution; Preferably, the amino acid sequence of the hRSV F protein before fusion includes at least one of S155C substitution, S190F substitution, V207L substitution, S290C substitution, and / or the P27 sequence of the hRSV F protein before fusion is replaced with a GS sequence; Preferably, the amino acid sequence of the hRSV F protein before fusion includes S155C substitution, S190F substitution, V207L substitution, and S290C substitution; the P27 sequence of the hRSV F protein before fusion is replaced with the GS sequence shown in Seq ID NO.74; the hRSV F protein before fusion includes a multimerization element as shown in one of Seq ID NO.7 and Seq ID NO.12; Preferably, the amino acid sequence of the hRSV F protein before fusion includes S155C substitution, S190F substitution, V207L substitution, and S290C substitution; the P27 sequence of the hRSV F protein before fusion is replaced with the GS sequence shown in Seq ID NO.74; the hRSV F protein before fusion includes a multimerization element as shown in one of Seq ID NO.7 and Seq ID NO.12; the amino acid sequence of the hRSV F protein before fusion also includes at least one of S46G substitution, N67I substitution, E92D substitution, P102A substitution, A149C substitution, L373R substitution, S215P substitution, I379V substitution, M447V substitution, Y458C substitution, K465Q substitution, D486C substitution, and D489C substitution; Preferably, the amino acid sequence of the hRSV F protein before fusion includes at least one of S155C substitution, S190F substitution, V207L substitution, S290C substitution, D486C substitution, and D489C substitution, and / or the P27 sequence of the hRSV F protein before fusion is replaced with a GS sequence; Preferably, the amino acid sequence of the hRSV F protein before fusion includes S155C substitution, S190F substitution, V207L substitution, S290C substitution, D486C substitution, and D489C substitution, and the P27 sequence of the hRSV F protein before fusion is replaced with the GS sequence shown in Seq ID NO.74, and the hRSV F protein before fusion includes a multimerization element as shown in one of Seq ID NO.7 and Seq ID NO.12; Preferably, the amino acid sequence of the hRSV F protein before fusion includes S155C substitution, S190F substitution, V207L substitution, S290C substitution, D486C substitution, and D489C substitution, and the P27 sequence of the hRSV F protein before fusion is replaced with the GS sequence shown in Seq ID NO.74, and the hRSV F protein before fusion includes a multimerization element as shown in Seq ID NO.7 and Seq ID NO.12; the amino acid sequence of the hRSV F protein before fusion also includes at least one of S46G substitution, N67I substitution, E92D substitution, P102A substitution, A149C substitution, L373R substitution, S215P substitution, I379V substitution, M447V substitution, Y458C substitution, and K465Q substitution.
4. The immune composition according to claim 1 or 2, characterized in that The hRSV F protein before fusion includes an amino acid sequence in which at least one of the amino acids of the F2 sequence, the RR1 sequence, the RR2 sequence, the 525-529 sequence or the 551-574 sequence is continuously or intermittently deleted.
5. The immune composition according to claim 1 or 2, characterized in that The amino acid sequences of the hRSV F proteins before fusion are shown in Seq ID NO.62, Seq ID NO.64, Seq ID NO.66, Seq ID NO.68, Seq ID NO.70, Seq ID NO.72, Seq ID NO.76, and Seq ID NO.78; Preferably, the amino acid sequence of the hRSV F protein before fusion is shown in Seq ID NO.62, Seq ID NO.64, Seq ID NO.66, Seq ID NO.70, Seq ID NO.76, and Seq ID NO.78; Preferably, the amino acid sequence of the hRSV F protein before fusion is shown in Seq ID NO.62, Seq ID NO.66, Seq ID NO.70, Seq ID NO.76, and Seq ID NO.
78.
6. The immune composition according to claim 5, characterized in that The multimerization element of the pre-fusion hRSV F protein can also be selected from the amino acid sequences shown in Seq ID NO.1-12 and Seq ID NO.14-15.
7. The immune composition according to claim 1 or 2, characterized in that The immune composition is a nucleic acid immune composition; the nucleic acid immune composition comprises nucleic acid molecules; the nucleic acid molecules comprise DNA molecules and / or RNA molecules; preferably, the DNA molecules comprise chain DNA molecules and / or circular DNA molecules; Preferably, the RNA molecule comprises mRNA or circular RNA; Preferably, the mRNA molecule comprises an open reading frame (ORF), and the nucleotide sequence of the open reading frame (ORF) is shown in Seq ID NO.63, Seq ID NO.65, Seq ID NO.67, Seq ID NO.69, Seq ID NO.71, Seq ID NO.73, Seq ID NO.77, Seq ID NO.79, and Seq ID NOs.84 to 103; Preferably, the mRNA molecule comprises an open reading frame (ORF), and the nucleotide sequence of the open reading frame (ORF) is shown in Seq ID NO.63, Seq ID NO.67, Seq ID NO.71, Seq ID NO.77, Seq ID NO.79, and Seq ID NOs.84 to 103; Preferably, the mRNA molecule comprises an open reading frame (ORF), and the nucleotide sequence of the open reading frame (ORF) is shown in Seq ID NO.63, Seq ID NO.71, Seq ID NO.77, Seq ID NO.79, Seq ID NO.84-87, Seq ID NO.92-103; Preferably, the mRNA molecule comprises an open reading frame (ORF), and the nucleotide sequence of the open reading frame (ORF) is shown in Seq ID NO.63, Seq ID NO.77, Seq ID NO.79, Seq ID NO.84-87, Seq ID NO.96-103; Preferably, the mRNA molecule comprises an open reading frame (ORF), and the nucleotide sequence of the open reading frame (ORF) is shown in Seq ID NO.67; Preferably, the mRNA molecule comprises an open reading frame (ORF), and the nucleotide sequence of the open reading frame (ORF) is shown in Seq ID NO.71; Preferably, in some embodiments, the nucleotide sequence of the multimerization element in the open reading frame (ORF) can also be as shown in Seq ID NO.36-47 and Seq ID NO.
13.
8. The immune composition according to claim 1 or 2, characterized in that The immune composition comprises a delivery preparation; preferably, the delivery preparation comprises lipid nanoparticles or cationic liposomes.
9. The method for preparing the immune composition according to claim 7, characterized in that: The mRNA and a delivery formulation are mixed to form an immunological composition; the delivery formulation comprises lipid nanoparticles or cationic liposomes.
10. An isolated mRNA, characterized in that The coding region nucleic acid sequence of the mRNA encodes a pre-fusion hRSV F protein, and the amino acid sequence of the pre-fusion hRSV F protein includes a TM sequence and a multimerization element; preferably, the amino acid sequence of the multimerization element is as shown in Seq ID NO.1-12 and Seq ID NO.14-15; preferably, the amino acid sequence of the multimerization element is as shown in one of Seq ID NO.7 and Seq ID NO.12; Preferably, the mRNA further comprises: at least one of: a 5' end cap, a 5' UTR, a 3' UTR and a 3' end poly A tail; Preferably, the 5' end cap is selected from ARCA, mCAP, dmCAP, tmCAP, m7G(5"")ppp(5"")(2""OMeA)pG, m7(3""OMeG)(5"")ppp(5"")(2""OMeA)pG, m7(3""OMeG)(5"")ppp(5"")(2""OMeG)pG, dmCAP or m7G(5"")ppp(5"")(2""OMeG)pG; Preferably, the length of the polyA tail at the 3' end is 50 to 200; preferably, the length of the polyA tail at the 3' end is 80 to 200; preferably, the length of the polyA tail at the 3' end is 80 to 120; preferably, the length of the polyA tail at the 3' end is 120; Preferably, the length of the 5'UTR is preferably 10 to 200 nucleotides, preferably 15 to 100 nucleotides; preferably, the 5'UTR nucleotide sequence is as shown in Seq ID NO.16-18; preferably, the 5'UTR nucleotide sequence is as shown in Seq ID NO.16; Preferably, the 3'UTR sequence is as shown in Seq ID NO.19 to 21; Preferably, the 3'UTR sequence is as shown in Seq ID NO.19; Preferably, one or more uridines in the mRNA are replaced with modified nucleosides; preferably, the modified nucleosides are pseudouridine (ψ), N1-methyl-pseudouridine (m1ψ) or 5-methyl-uridine (m5U)(m5U); preferably, the modified nucleosides are N1-methyl-pseudouridine (m1ψ).
11. An isolated DNA, characterized in that The DNA is obtained by reverse transcription of the mRNA nucleic acid isolated as claimed in claim 10, or the DNA is a sequence that can transcribe the mRNA isolated as claimed in claim 10.
12. A biological material, comprising any one of an expression cassette, a vector, an engineered bacterium or a cell line, wherein the biological material contains or expresses the mRNA isolated according to claim 10 or the DNA isolated according to claim 11.
Citation Information
Patent Citations
RSV f protein compositions and methods for making same
CA2768186A1
Prefusion RSV F proteins and their use
CN105473604A
Stabilized soluble pre-fusion RSV f proteins
CN109069616A
Stabilized soluble pre-fusion RSV F polypeptides
CN110590916A
Stabilized RSV F proteins and uses thereof
CN111655715A
